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Figure S1. ODD-Luc degradation western blot assay. HeLa cells stably expressing the UbG76V-
GFP and ODD-Luc reporters were grown in 6 well plates. Cells were treated with MG132 (4 μM 
for 1 h) to accumulate reporter, washed, and exposed to the indicated test compounds plus CHX 
to initiate a chase. After 2h, cells were harvested and evaluated by immunoblotting for the 
remaining ODD-Luc (right panel). The Ponceau S-stained filters serve as loading controls (left 
panel). In the figure test compounds are identified using the “KU-SCC #”, where each two part 
identifier is prefixed with the letter code KSC. Compound structures can be found in the 





















        






1# 886813 87796231 
KSC-1-
150 P H 2-F H H H 3±0.8 9.0±1.3 
S2 
2# 1894007 87796228 
KSC-1-
146 P H 2-Cl H H H 1.2±0.6 8±3 
S3 
3# 2927831 87796230 
KSC-1-
149 P H 3-NO2 H H H 5.9±3 4.0±1.6 
S4 780643 87796227 KSC-1-145 P H H H H H 4.2±2.3 12±3 
S5 4084712 87796265 KSC-1-226 P H 3-Me H H H 4.2±0.2 17±4 
S6 1591117 87796273 KSC-1-236 P H 4-Cl H H H 5.5±1.9 20±3 
S7 1187251 87796271 KSC-1-234 P H 4-NO2 H H H 11±6 19±7 
S8 949742 87796266 KSC-1-227 P H 4-OMe H H H 1.6±0.3 15±2 
S9 3395671 87796263 KSC-1-224 P H 4-Me H H H 5.7±0.7 13±2 
S10 2452802 87796251 KSC-1-212 P H H H H 4-F 11±3 19±3 
S11 20963125 87796258 KSC-1-219 P H 4-OMe H H 4-F 7.8±0.4 9.8±3 
S12 20963158 87796259 KSC-1-220 P H 4-OMe H H 4-OMe 13±4 15±5 
S13 20963177 87796260 KSC-1-221 P H 4-OMe H H 4-Me 8±2 12±2 
S14 20963187 87796261 KSC-1-222 P H 4-OMe H H 4-Cl 8±2 9.3±1 
S15 20963255 87796262 KSC-1-223 P H 4-Cl H H 4-F 8±0.2 20±5 
S16 4084711 87796264 KSC-1-225 P H 3-Me H H 4-F 15±2 12±0.8 
S17 2790952 87796274 KSC-1-237 P H 4-Me H Me H 7±4 17±4 
S18 15992808 87796255 KSC-1-216 P H 2-F H Me H >30 15±4 
S19 
4# 8074678 87796236 
KSC-1-
193 P 7-Cl H H H H 70±24 12±4 
S20 
5# 8080035 87796237 
KSC-1-
194 P 7-Cl 4-Me H H H 39±13 24±5 
S21 8080040 87796238 KSC-1-195 P 7-Cl 4-OMe H H H 25±11 70±30 
S‐7 
 
S22 2454628 87796252 KSC-1-213 P H H CH2 H 2-CH2 >30 19±5 
S23 2047240 87796235 KSC-1-147 P H 4-Br H H H 72±14 25±10 
S24 2178012 87796229 KSC-1-148 P H 2-NO2 Me H H 25±11 11±6 
S25 1819025 87796240 KSC-1-200 P H 3,4-Di-Cl H H H 7.1±0.4 37±6 
S26 2452792 87796250 KSC-1-211 P H H H H 3-Cl 28±9 17±4 
S27 2465033 87796253 KSC-1-214 P H H H H 2-Cl 30±10 11±3 
S28 2456309 87796254 KSC-1-215 
P H H H H 4-Cl >30 15±3 
S29 15993188 87796256 KSC-1-217 P H 2-F H H 2-Cl 26±12 15±3 
S30 15995431 87796257 KSC-1-218 P H 2-F Me H H 25±4 6.0±2.0 
S31 1566144 87796272 KSC-1-235 
P H 4-NO2 Me H H 8.4±4 28±4 
S32 5051334 87796275 KSC-1-238 P 
H H H Me H 27±14 13±1 
S33 1895905 87796288 KSC-1-257 P H 2,4-Di-Cl H H H >30 11±0.8 
S34 
8# 1553819 87796289 
KSC-1-
258 
P H H Me H H 49±17 17±5 
* Designates whether a compound was purchased (P) or synthesized (S) 
# Compound identifier used in the main text. 
 
Table S2: Analogues of N2, N4-disubstitued quinazoline-2,4-diamine 
compound identifiers p97 inhibition 






6# 696840 87796233 KSC-1-152 P 26±4 7.3±2 
S36 
7# 832282 87796232 KSC-1-151 P 23±6 36±9 
S37 2950240 87796276 KSC-1-240 P 34±10 36±0.3 
S‐8 
 
S38 832283 92093143 KSC-1-260 P 53±18 31±6 
S39 1330669 87796248 KSC-1-208 P 34±11 35±5 
S40 1337599 92093137 KSC-1-203 P 33±8 12±1 
S41 1091839 92093140 KSC-1-242 P 57±15 56±10 
S42 2955641 87796277 KSC-1-241 P 22±12 39±18 
S43 5051334 87796275 KSC-1-239 P 43±13 70±16 
S44 2932797 92093142 KSC-1-254 P 30±6 34±6 
S45 46873814 99313590 KSC-16-190 S >30 8.1±1.8 
S46 49830268 103904170 KSC-16-272 S >30 >20 
S‐9 
 
S47 49830259 103904173 KSC-16-277 S 7±3 >20 
S48 49852179 104221944 KSC-25-10 S 31±7 47±9 
S49 49852178 104221946 KSC-25-16 S >30 45±18 
* Designates whether a compound was purchased (P) or synthesized (S) 
# Compound identifier used in the main text. 
 
 
Table S3: Analogues of N2 , N4-diphenylquinazoline-2,4-diamine 
compound identifiers p97 inhibition 
Cpd CID SID KU SCC # * R1 R2 ATPase IC50 (µM) 
UbG76V-GFP
IC50 (µM) 
S50 17324423 99239924 KSC-16-149 S 4-OMe 4-OMe 22±4 23±3 
S51 46850879 99239936 KSC-16-163 S 3-Cl H 34±16 12±2 
S52 46850870 99239937 KSC-16-164 S 3-Cl 4-OMe 34±14 13±1 
S53 46850872 99239940 KSC-16-174 S 3-Cl 4-Me 49±19 30±4 
S54 46850878 99239942 KSC-16-176 S 3-Cl 4-Cl 117±5.8 21±2 
S55 46850875 99239944 KSC-16-151 S 4-Me 4-Me 54±19 21±4 
S56 
9# 
213847 99206554 KSC-16-146 S H H 2.6±0.8 7.2±1 
S57 1878549 87796278 KSC-1-243 P 4-Cl 4-Cl 52±10 19±4 
* Designates whether a compound was purchased (P) or synthesized (S) 





Table S4 : Analogues of N4-benzyl-N2-phenylquinazoline-2,4-diamine 










10# 2909934 87796234 KSC-1-153 P H 2.3±1 3.1±0.4 
S59 929548 87796285 KSC-1-251 P 4-Me 2.2±0.4 6.3±1.4 
S60 2351737 87796281 KSC-1-246 P 4-Cl 5.4±2 5.9±1.2 
S61 797650 87796284 KSC-1-249 P 4-F 3.8±1.2 9.4±1 
S62 1943389 87796280 KSC-1-245 P 4-Br 1.8±0.4 6.0±0.8 
S63 1330474 92093141 KSC-1-250 P 4-OMe 3.8±0.5 4.5±1.1 
S64 949445 87796286 KSC-1-252 P 2-Me 3.4±1.5 10±2 
S65 886196 87796282 KSC-1-247 P 2-F 0.85±0.17 10±2 
S66 1415819 87796283 KSC-1-248 P 2-OMe 2.2±0.9 11±3 
S67 950033 87796287 KSC-1-253 P 3-Me 1.7±0.5 3.0±0.7 
S68 
11# 1633082 87796279 KSC-1-244 P 3-Cl 0.48±0.16 7.8±1.3 
S69 1571079 87796290 KSC-1-259 P 3,4-di-Cl 8.1±2.6 12±2 
S70 1330474 92252642 KSC-1-290 S 4-OMe 3.5±0.5 4.8±0.7 
S71 45108365 92252645 KSC-1-293 S 3-Br 2.5±0.5 4.3±0.8 
S72 39861404 92252643 KSC-1-291 S 3-OMe 2.5±0.2 4.3±0.7 
S73 46850871 99239933 KSC-16-155 S 3-NO2 5.2±0.5 19±2 
S74 
44# 11645888 92252644 KSC-1-292 S 3-F 1.6±0.1 2.7±0.4 
S75 45108364 92252647 KSC-1-295 S 3-Cl-6-F 13±3 13±2 
S76 45108364 92252647 KSC-1-294 S 3,5-di-Cl 8.2±0.3 13±1 
S77 46224527 96079523 KSC-16-103 S 3-Cl-2-OMe 0.9±0.2 6.3±1.7 
S78 46224522 96079524 KSC-16-104 S 3-F-2-Me 0.9±0.1 3.7±0.8 
S79 46224524 96079525 KSC-16-105 S 3-F-5-Me 0.7±0.05 5.4±0.8 
S‐11 
 
S80 46224529 96079526 KSC-16-106 S 3-F-2-OMe 1.7±0.5 12±3 
S81 46224523 96079527 KSC-16-107 S 3-Cl-2-Me 0.7±0.1 5.5±1 
S82 46224519 96079528 KSC-16-108 S 3-F-6-Me 0.8±0.1 5±1 
S83 46224528 96079529 KSC-16-109 S 3-F-4-Me 0.9±0.2 5.2±1.2 
S84 46224530 96079530 KSC-16-110 S 3-F-4-OMe 0.9±0.1 4.7±0.8 
S85 46224526 96079531 KSC-16-112 S 3-Cl-6-Me 0.8±0.07 7±1.5 
S86 46224518 96079532 KSC-16-113 S 3-Cl-6-OMe 1.1±0.2 16±6 
S87 46829342 99206553 KSC-16-120 S 3-F-6-OMe 6.7±3 9.3±1 
S88 45108363 92252640 KSC-1-288 S 2-Br 64±24 13±2 
S89 2384230 92252641 KSC-1-289 S 2-Cl 69±25 13±2 
S90 46829335 99239925 KSC-16-150 S 3-CF3 50±16 21±1 
S91 46850881 99239930 KSC-16-152 S 3-I 5.2±1.9 36±4 
S92 46873821 99313588 KSC-16-188 S >30 9.2±1.2 
* Designates whether a compound was purchased (P) or synthesized (S) 
# Compound identifier used in the main text. 
 
Table S5: Analogues of N4-benzyl-N2-(3-chlorophenyl)quinazoline-2,4-diamine 
 
compound identifiers  
 
 p97 inhibition 
Cpd CID SID KU SCC # * R1 ATPase IC50 (µM) 
UbG76VGFP 
IC50 (µM) 
S93 46173070 96022083 KSC-16-72 S 4-Me 1.4±0.3 12±2 
S94 46173066 96022090 KSC-16-89 S 4-Cl 2.8±0.9 7.6±2.4 
S95 
12# 
46173057 96022093 KSC-16-98 S 4-F 1.5±0.3 5.7±1.3 
S96 46173059 96022096 KSC-16-101 S 4-Br 7.4±2 10±3 
S97 46173063 96022086 KSC-16-79 S 4-OMe 2.3±0.6 11±4 
S‐12 
 
S98 46173069 96022080 KSC-16-63 S 2-Me 4.2±1.1 11±3 
S99 46173062 96022087 KSC-16-84 S 2-Cl 4.7±1.4 18±5 
S100 46173072 96022091 KSC-16-92 S 2-F 1.8±0.5 7.8±2.1 
S101 46173058 96022094 KSC-16-99 S 2-Br 4±1.7 12±5 
S102 46173067 96022084 KSC-16-75 S 2-OMe 1.6±0.4 11±2 
S103 46173061 96022081 KSC-16-66 S 3-Me 2.3±0.6 9.7±2.7 
S104 46173068 96022088 KSC-16-87 S 3-Cl 5±1.2 15±4 
S105 46173060 96022092 KSC-16-95 S 3-F 1.2±0.2 6.3±1.7 
S106 46173065 96022095 KSC-16-100 S 3-Br 3.7±0.9 9.9±2 
S107 46173071 96022085 KSC-16-78 S 3-OMe 1±0.1 9.9±1.6 
* Designates whether a compound was purchased (P) or synthesized (S) 
# Compound identifier used in the main text. 
 








13# 45382111 93374187 KSC-16-2 S 4-OMe 3±0.5 1.3±0.2 
S109 
45# 
25144450 93374186 KSC-1-300 S 4-Me 3±0.3 1.5±0.4 
S110 45382112 93374224 KSC-16-33 S 4-Cl 3.1±0.2 2.1±0.4 
S111 45382121 93374227 KSC-16-38 S 4-F 2.6±0.2 3.4±0.5 
S112 45382119 93374230 KSC-16-42 S 4-Br 4.3±0.9 3.9±0.3 
S113 45382120 93374191 KSC-16-8 S 2-Me 2.7±0.5 1.9±0.4 
S114 45382117 93374222 KSC-16-31 S 2-Cl 5.3±1.2 2.9±0.9 
S‐13 
 
S115 45382108 93374225 KSC-16-35 S 2-F 2.9±0.4 2.8±0.4 
S116 45382107 93374228 KSC-16-40 S 2-Br 2.0±0.3 3.8±0.7 
S117 45382105 93374193 KSC-16-29 S 2-OMe 3.6±0.8 1.9±0.2 
S118 45382113 93374192 KSC-16-28 S 3-Me 2.3±0.4 2.5±0.5 
S119 45382114 93374223 KSC-16-32 S 3-Cl 2.7±0.1 2.5±0.4 
S120
46# 45382109 93374190 KSC-16-6 S 4-CF3 2.6±0.4 2.3±0.3 
S121
47# 45382116 93374221 KSC-16-30 S 3-OMe 4.5±0.8 2.5±0.8 
S122
48# 45382110 93374226 KSC-16-36 S 3-F 3.1±0.4 2.8±0.4 
S123
49# 45382118 93374229 KSC-16-41 S 3-Br 3.7±0.4 2.8±0.4 
S124 45382106 93374188 KSC-16-3 S 3,4-di-Cl 3±0.5 1.9±0.2 
S125 45382115 93374189 KSC-16-4 S 4-Cl-3-CF3 4.7±1 2.2±0.4 
* Designates whether a compound was purchased (P) or synthesized (S) 
# Compound identifier used in the main text. 
 
Table S7: Analogues of N2,N4-dibenzylquinazoline-2,4-diamine (DBeQ) 
compound identifiers p97 inhibition 




46224525 96079533 KSC-16-114 S 5-Cl 2.2±0.7 16±2 
S127 46224521 96079534 KSC-16-115 S 5-F 1.2±0.3 13±2 
S128 46224520 96079535 KSC-16-117 S 6-Cl 1.6±0.4 6.6±0.9 
S129 5276745 96022097 KSC-16-102 S 6,7-di-OMe 4.4±1.8 8.8±1.5 
S130
14# 46829340 99206522 
KSC-16-
121c S 8-OMe 0.6±0.06 10±2 
S131 46829333 99206552 KSC-16-118 S 7-Me 2.2±0.4 6.1±1.6 
S‐14 
 
S132 46850874 99239928 
KSC-16-
160c S 7-CF3 9.1±2 19±1 
S133 46850882 99239931 KSC-16-153 S 8-Br 3.3±0.9 30±2 
S134 46850883 99239932 KSC-16-154 S 8-F 3.1±0.5 18±2 
S135 46850884 99239934 KSC-16-156 S 7-F 2.6±0.5 6.1±0.8 
S136 46850880 99239935 KSC-16-159 S 7-Cl 5.5±0.9 6.3±0.9 
S137 46850885 99239938 KSC-16-166 S 7-OMe 5.7±1 42±6 
S138 46850877 99239939 KSC-16-172 S 6-OMe 7.5±1.1 8.6±1.7 
S139 46850873 99239941 KSC-16-175 S 6-F 4.7±0.4 8.2±1.5 
S140 4685087 99239943 KSC-16-122 S 7-Br 22±4 10±2 
S141 46850869 99239929 KSC-16-167C S 7-CN 25±10 21±3 
* Designates whether a compound was purchased (P) or synthesized (S) 
# Compound identifier used in the main text. 
 
Table S8: N2 Constrained DBeQ analogues 
compound identifiers  p97 inhibition  





S142 46829336 99239922 KSC-16-125 S H 1 C -H 4.4±1.8 10±2 




64 96022082 KSC-16-70 S H 1 O -H 0.6±0.2 7±1.9 
S145 46829338 99206557 KSC-16-147 S H 1 NH -H 0.4±0.05 6.3±1 









12 99437738 KSC-16-232 S 8-OH 1 O -H 1.2±0.3 7.7±1.7 
S149 
498302





























67 103904184 KSC-16-268 S
8-p-













1 O -H 0.4±0.08 7.7±0.7 
S156 
498521



























80 113284753 KSC-25-31 S
0.05±0.0
03 1.8±0.2 
* Designates whether a compound was purchased (P) or synthesized (S) 
** unsubstituted nitrogen of a benzimidazole moiety 












Table S9: Alternatives to the quinazoline scaffold analogues     
          
compound identifiers structure p97 inhibition 









































956 KSC-25-28 S 
 
2.9±0.2 27±3 
* Designates whether a compound was purchased (P) or synthesized (S) 




Table S10: Miscellaneous 8-methoxyquinazoline analogues  
compound identifiers 
 
p97 inhibition  









19# 49852183 104221949 KSC-25-21 S 
 
0.3±0.07 7.8±1.2 
S168 49852174 104221945 KSC-25-12 S 
 
49±10 108±31 




20# 25144452 99313587 KSC-16-187 S 
 
15±3 7±1.3 
S171 46931213 99437735 KSC-16-203 S 
 
2.6±0.4 2.8±0.5 
S172 49830269 103904171 KSC-16-273 S 
 
12±5 2.1±0.7 

















49830257 103904175 KSC-16-282 S 
 
1.7±0.4 1.8±0.3 
S177 49830266 103904176 KSC-16-283 S 
 
11±1 10±3 
S178 46873813 99313594 KSC-16-196 S 
 
1.5±0.2 7.1±0.5 
* Designates whether a compound was purchased (P) or synthesized (S) 
# Compound identifier used in the main text. 
 
 
Table S11: 3,4-Dihydro-1,4-benzoxazine analogues incorporating the quinazoline of ML241 
compound identifiers  
 
p97 inhibition  





























46931210 99437737 KSC-16-222 S 
 
4.6±1 6±0.6 
S184 46931211 99437740 KSC-16-235c2 S 
 
2.4±0.5 7.3±1 
S185 46931215 99437739 KSC-16-227 S 
 
47±22 4.5±0.5 





S187 49830254 103904179 KSC-16-251 S 
 
33±7 23±2 
S188 49852170 104221951 KSC-25-6 S 
 
38±7 20±3 
* Designates whether a compound was purchased (P) or synthesized (S) 
# Compound identifier used in the main text. 
 
Table S12: Unabridged compound purity assessment via HPLC analysis. 
internal compound ID compound number(s) HPLC purity (%)1
KSC-1-150 1, S1 100.0 
KSC-1-146 2, S2 100.0 
KSC-1-149 3, S3 94.5 
KSC-1-193 4, S19 99.2 
KSC-1-194 5, S20 99.5 
KSC-1-152 6, S35 92.0 
KSC-1-151 7, S36 100.0 
KSC-1-258 8, S34 100.0 
KSC-16-146 9, S56 98.8 
KSC-1-153 10, S58 99.1 
KSC-1-244 11, S68 96.7 
KSC-16-98 12, S95 100.0 
KSC-16-2 13, S108 96.8 
KSC-16-121c 14, S130 98.9 
KSC-16-70 15, S144 99.0 
KSC-206-026 16 96.1 
KSC-25-14 17, S162 95.3 
KSC-25-31 18, S161 81.2 
KSC-16-290 ML241 98.3 
KSC-16-270 ML240, S158 100.0 
KSC-25-21 19, S167 96.9 
KSC-16-187 20, S170 83.1 
KSC-25-40 21 95.6 
KSC-25-23 22 94.4 
KSC-25-38 23 97.8 
S‐21 
 
KSC-206-023 24 95.5 
KSC-206-022 25 93.2 
KSC-206-019 26 90.2 
KSC-206-017 27 98.8 
KSC-206-017-P2 28 96.8 
KSC-206-015 29 99.0 
KSC-206-007 30 98.8 
KSC-25-24 31, S163 100.0 
KSC-25-28 32, S165 100.0 
KSC-16-260 33, S150 100.0 
KSC-25-29 34, S151 98.0 
KSC-16-265 35, S152 68.2 
KSC-16-268 36, S153 92.9 
KSC-25-30 37, S154 100.0 
KSC-16-191 38, S147 100.0 
KSC-206-005 39, S155 96.0 
KSC-16-261 40, S179 98.8 
KSC-16-295 41,S180 96.6 
KSC-16-299 42, S181 95.0 
KSC-16-222 43, S183 100.0 
KSC-1-292 44, S74 100.0 
KSC-1-300 45, S109 97.6 
KSC-16-6 46, S120 99.0 
KSC-16-30 47, S121 100.0 
KSC-16-36 48, S122 100.0 
KSC-16-41 49, S123 99.0 
KSC-16-193 50, S174 98.9 
KSC-16-194 51, S175 100.0 
KSC-16-282 52, S176 100.0 
KSC-1-145 S4 100.0 
KSC-1-226 S5 100.0 
KSC-1-236 S6 100.0 
KSC-1-234 S7 94.8 
KSC-1-227 S8 98.5 
KSC-1-224 S9 100.0 
KSC-1-212 S10 92.5 
KSC-1-219 S11 96.8 
KSC-1-220 S12 95.5 
KSC-1-221 S13 97.5 
KSC-1-222 S14 100.0 
KSC-1-223 S15 98.1 
KSC-1-225 S16 100.0 
KSC-1-237 S17 98.9 
KSC-1-216 S18 100.0 
KSC-1-195 S21 99.3 
S‐22 
 
KSC-1-213 S22 100.0 
KSC-1-147 S23 99.1 
KSC-1-148 S24 100.0 
KSC-1-200 S25 100.0 
KSC-1-211 S26 100.0 
KSC-1-214 S27 97.7 
KSC-1-215 S28 100.0 
KSC-1-217 S29 100.0 
KSC-1-218 S30 100.0 
KSC-1-235 S31 100.0 
KSC-1-238 S32 100.0 
KSC-1-257 S33 96.6 
KSC-1-240 S37 100.0 
KSC-1-260 S38 100.0 
KSC-1-208 S39 100.0 
KSC-1-203 S40 100.0 
KSC-1-242 S41 81.2 
KSC-1-241 S42 98.2 
KSC-1-239 S43 96.1 
KSC-1-254 S44 96.5 
KSC-16-190 S45 97.7 
KSC-16-272 S46 100.0 
KSC-16-277 S47 98.6 
KSC-25-10 S48 100.0 
KSC-25-16 S49 98.2 
KSC-16-149 S50 96.2 
KSC-16-163 S51 100.0 
KSC-16-164 S52 100.0 
KSC-16-174 S53 98.4 
KSC-16-176 S54 97.8 
KSC-16-151 S55 100.0 
KSC-1-243 S57 100.0 
KSC-1-251 S59 100.0 
KSC-1-246 S60 100.0 
KSC-1-249 S61 100.0 
KSC-1-245 S62 97.7 
KSC-1-250 S63 91.5 
KSC-1-252 S64 100.0 
KSC-1-247 S65 97.7 
KSC-1-248 S66 96.1 
KSC-1-253 S67 100.0 
KSC-1-259 S69 100.0 
KSC-1-290 S70 92.1 
KSC-1-293 S71 98.5 
KSC-1-291 S72 99.0 
S‐23 
 
KSC-16-155 S73 100.0 
KSC-1-295 S75 98.2 
KSC-1-294 S76 98.6 
KSC-16-103 S77 96.3 
KSC-16-104 S78 100.0 
KSC-16-105 S79 100.0 
KSC-16-106 S80 97.6 
KSC-16-107 S81 99.0 
KSC-16-108 S82 100.0 
KSC-16-109 S83 100.0 
KSC-16-110 S84 100.0 
KSC-16-112 S85 100.0 
KSC-16-113 S86 96.4 
KSC-16-120 S87 96.5 
KSC-1-288 S88 100.0 
KSC-1-289 S89 100.0 
KSC-16-150 S90 100.0 
KSC-16-152 S91 100.0 
KSC-16-188 S92 100.0 
KSC-16-72 S93 100.0 
KSC-16-89 S94 100.0 
KSC-16-101 S96 100.0 
KSC-16-79 S97 100.0 
KSC-16-63 S98 100.0 
KSC-16-84 S99 100.0 
KSC-16-92 S100 100.0 
KSC-16-99 S101 100.0 
KSC-16-75 S102 100.0 
KSC-16-66 S103 100.0 
KSC-16-87 S104 100.0 
KSC-16-95 S105 100.0 
KSC-16-100 S106 100.0 
KSC-16-78 S107 100.0 
KSC-16-38 S111 100.0 
KSC-16-42 S112 98.1 
KSC-16-8 S113 97.5 
KSC-16-31 S114 98.9 
KSC-16-35 S115 97.7 
KSC-16-40 S116 100.0 
KSC-16-29 S117 97.3 
KSC-16-28 S118 97.2 
KSC-16-32 S119 98.4 
KSC-16-33 S110 98.4 
KSC-16-3 S124 97.4 
KSC-16-4 S125 98.6 
S‐24 
 
KSC-16-114 S126 100.0 
KSC-16-115 S127 99.0 
KSC-16-117 S128 100.0 
KSC-16-102 S129 100.0 
KSC-16-118 S131 92.0 
KSC-16-160c S132 98.6 
KSC-16-153 S133 100.0 
KSC-16-154 S134 100.0 
KSC-16-156 S135 100.0 
KSC-16-159 S136 100.0 
KSC-16-166 S137 100.0 
KSC-16-172 S138 93.2 
KSC-16-175 S139 98.0 
KSC-16-122 S140 96.8 
KSC-16-167c S141 97.5 
KSC-16-125 S142 96.1 
KSC-16-144 S143 94.8 
KSC-16-147 S145 60.6 
KSC-16-182 S146 19.5 
KSC-16-232 S148 100.0 
KSC-16-255 S149 95.6 
KSC-25-17 S156 75.0 
KSC-25-15c1 S157 96.5 
KSC-16-262cc S159 93.9 
KSC-25-3 S160 99.2 
KSC-25-32 S164 84.4 
KSC-25-22 S166 97.9 
KSC-25-12 S168 98.8 
KSC-25-19 S169 91.1 
KSC-16-203 S171 100.0 
KSC-16-273 S172 100.0 
KSC-16-278 S173 93.5 
KSC-16-283 S177 100.0 
KSC-16-196 S178 100.0 
KSC-16-219 S182 94.9 
KSC-16-235c2 S184 95.6 
KSC-16-227 S185 91.5 
KSC-16-243 S186 81.3 
KSC-16-251 S187 97.0 
KSC-25-6 S188 98.4 
1 Compound purity was measured on the basis of peak integration (area under the 
curve) from UV/vis absorbance (at 214 nm), and compound identity was determined on 












51# KSC-16-294 0.09/<0.01/<0.01 
S84 KSC-16-110 3.4/0.03/0.08 
S79 KSC-16-105 0.05/<0.01/<0.01 
S82 KSC-16-108 5.6/0.07/0.04 
S68 
11# KSC-1-244 0.04/0.01/0.02 
S144 
15# KSC-16-70 25.2/0.72/0.48 
S‐26 
 
S-83 KSC-16-109 0.13/0.04/0.05 
S78 KSC-16-104 8.4/0.05/<0.01 
S146 KSC-16-182 28.2/10.2/0.30 
S174 
50# KSC-16-193 0.08/0.05/<0.01 
S77 KSC-16-103 0.50/0.23/0.06 
S130 
14# KSC-16-121c 3.2/1.0/0.03 
S‐27 
 







S71 KSC-1-293 0.03/0.01/<0.01 
S116 KSC-16-40 0.21/0.24/0.14 
S123 
49# KSC-16-41 0.37/0.25/0.17 




ML240# KSC-16-270 0.06/0.09/0.05 
S159 KSC-16-262cc 0.02/<0.01/<0.01 
S150 KSC-16-260 21.5/0.48/0.43 
ML241# 
 KSC-16-290 28/0.13/0.20 
1 in aqueous PION’s buffer, pH’s 5.0/6.2/7.4 
# Compound identifier used in the main text. 
 
Table S14: Kinase/ATPase profiling for ML240 and ML241. 











[Homo sapiens (Human)]  YSLTVAVkTLKEDTMEVEEFLK  Lys1  11.1  5.3 
ACK 
Activated CDC42 kinase 1 [Homo sapiens 
(Human)]  TVSVAVkCLKPDVLSQPEAMDDFIR  Lys1  18.9  ‐11.3 
AGK 
Acylglycerol kinase, mitochondrial n=2 
Tax=Homo sapiens RepID=AGK_HUMAN  ATVFLNPAACkGK  ATP  7.5  5.2 
AMPKa1 
5'‐AMP‐activated protein kinase catalytic 








subunit alpha‐1 [Homo sapiens (Human)]  DLkPENVLLDAHMNAK  Lys2  ‐1.5  ‐0.9 
AMPKa2 
5'‐AMP‐activated protein kinase catalytic 
subunit alpha‐2 [Homo sapiens (Human)]  IGHYVLGDTLGVGTFGkVK  ATP Loop  11.9  ‐6.2 











R  ATP  ‐4.3  ‐8.3 
ATR 
Serine/threonine‐protein kinase ATR [Homo 









sapiens (Human)]  FILALkVLFK  Lys1  10.3  ‐1.8 
AurA 
Serine/threonine‐protein kinase 6 [Homo 
sapiens (Human)]  DIkPENLLLGSAGELK  Lys2  11.9  ‐1 
AurB 
Serine/threonine‐protein kinase 12 [Homo 
sapiens (Human)]  SHFIVALkVLFK  Lys1  ‐32.8  ‐14.3 
BARK1 
Beta‐adrenergic receptor kinase 1 n=1 




[Homo sapiens (Human)]  QLLDDHkDVVTLLAEGLR  Other  ‐9.9  ‐9.4 
BRAF 
B‐Raf proto‐oncogene serine/threonine‐
protein kinase [Homo sapiens (Human)]  DLkSNNIFLHEDLTVK  Lys2  10.5  14.3 
CaMK1a 
Calcium/calmodulin‐dependent protein kinase 
type 1 [Homo sapiens (Human)]  LVAIkCIAK  Lys1  ‐2.1  1.2 
CaMK1d 
Calcium/calmodulin‐dependent protein kinase 














RepID=KCC2D_HUMAN  IPTGQEYAAkIINTK  Lys1  ‐14.3  ‐17.7 
CaMK2g 
Calcium/calmodulin‐dependent protein kinase 
type II gamma chain [Homo sapiens (Human)]  KTSTQEYAAkIINTKK  Lys1  ‐8.6  ‐9.5 
CaMK2g 
Calcium/calmodulin‐dependent protein kinase 
type II gamma chain [Homo sapiens (Human)]  TSTQEYAAkIINTK  Lys1  7.5  6.7 
CaMKK1 
Calcium/calmodulin‐dependent protein kinase 
kinase 1 [Homo sapiens (Human)]  LAYNESEDRHYAMkVLSK  Lys1  ‐24.9  ‐7.1 
CaMKK2 
Calcium/calmodulin‐dependent protein kinase 
kinase 2 [Homo sapiens (Human)]  LAYNENDNTYYAMkVLSK  Lys1  ‐5.8  0.1 
CASK 
Peripheral plasma membrane protein CASK 
n=2 Tax=Catarrhini RepID=CSKP_HUMAN  ETGQQFAVkIVDVAK  Lys1  5.7  ‐0.4 
CCRK 
Cell cycle‐related kinase [Homo sapiens 
(Human)]  DLkPANLLISASGQLK  Lys2  2.1  4.4 
CDC2 
Cell division control protein 2 homolog [Homo 
sapiens (Human)]  DLkPQNLLIDDKGTIK  Lys2  ‐2.6  ‐6.5 
CDK10 
Cell division protein kinase 10 [Homo sapiens 




(Human)]  DLkPANILVMGEGPER  Lys2  ‐2.3  ‐5.3 
CDK2 
Cell division protein kinase 2 [Homo sapiens 
(Human)]  LTGEVVALkK  Lys1  ‐9.5  ‐2.8 
CDK2 
Cell division protein kinase 2 [Homo sapiens 
(Human)]  NKLTGEVVALKk  Lys1  15.7  3.7 
CDK2 
Cell division protein kinase 2 [Homo sapiens 
(Human)]  DLkPQNLLINTEGAIK  Lys2  ‐0.8  ‐1.9 
CDK5 
Cell division protein kinase 5 [Homo sapiens 
(Human)]  ETHEIVALkR  Lys1  ‐20.3  ‐10.8 
CDK5 
Cell division protein kinase 5 [Homo sapiens 





(Human)]  DLkPQNLLINR  Lys2  10.7  ‐5.6 
CDK7 
Cell division protein kinase 7 [Homo sapiens 
(Human)]  DLkPNNLLLDENGVLK  Lys2  2.5  ‐1.7 
CDK9 
Cell division protein kinase 9 [Homo sapiens 
(Human)]  DMkAANVLITR  Lys2  ‐14.5  ‐15.3 
CHED 
Cell division cycle 2‐like protein kinase 5 
[Homo sapiens (Human)]  DIkCSNILLNNRGQIK  Lys2  17.4  2.7 
CHK1 
Serine/threonine‐protein kinase Chk1 [Homo 
sapiens (Human)]  LSkGDGLEFK  Other  ‐4.2  ‐3.2 
CHK2 
Serine/threonine‐protein kinase Chk2 [Homo 
sapiens (Human)]  VAIkIISK  Lys1  ‐4.9  ‐5.4 
CHK2 
Serine/threonine‐protein kinase Chk2 [Homo 
sapiens (Human)]  DLkPENVLLSSQEEDCLIK  Lys2  3.1  4.2 
CK1a 
Casein kinase I isoform alpha [Homo sapiens 




(Human)]  DVkPDNFLMGLGKK  Lys2  ‐1.5  ‐4.8 
CK2a2 
Casein kinase II subunit alpha' [Homo sapiens 
(Human)]  DVkPHNVMIDHQQK  Lys2  ‐11.7  ‐34.4 
CLK2 
Dual specificity protein kinase CLK2 [Homo 
sapiens (Human)]  LTHTDLkPENILFVNSDYELTYNLEK  Lys2  ‐12.9  ‐5.9 
CRK7 
Cell division cycle 2‐related protein kinase 7 


















subunit [Homo sapiens (Human)]  GHDEREHPFLVkGGEDLRQDQR  ATP  12.4  1.7 
DNAPK 
DNA‐dependent protein kinase catalytic 


















































sapiens (Human)]  DLkPSNLLINTTCDLK  Lys2  3.6  3.5 
Erk1,Erk2 
Mitogen‐activated protein kinase 3 [Homo 
sapiens (Human)]  YIHSANVLHRDLkPSNLLINTTCDLK  Lys2  ‐12.2  8.6 
Erk1,Erk2 
Mitogen‐activated protein kinase 1 [Homo 
sapiens]  YIHSANVLHRDLkPSNLLLNTTCDLK  Lys2  ‐10  5.3 
Erk5 
Mitogen‐activated protein kinase 7 n=2 
Tax=Homo sapiens RepID=MK07_HUMAN  DLkPSNLLVNENCELK  Lys2  ‐14.3  ‐6.4 
















n=2 Tax=Homo sapiens RepID=FER_HUMAN  TSVAVkTCKEDLPQELK  Lys1  4.8  ‐1.8 
FRAP 
FKBP12‐rapamycin complex‐associated 
protein [Homo sapiens (Human)]  IQSIAPSLQVITSkQRPR  ATP  22.6  ‐0.2 
FYN 
Proto‐oncogene tyrosine‐protein kinase Fyn 


























kinase 4 [Homo sapiens (Human)]  DLkPVNIFLDSDDHVK  Lys2  12.6  1 
GSK3A 
Glycogen synthase kinase‐3 alpha [Homo 
sapiens (Human)]  DIkPQNLLVDPDTAVLK  Lys2  2  0 
GSK3B 
Glycogen synthase kinase‐3 beta n=2 




precursor [Homo sapiens (Human)]  GIWIPDGENVKIPVAIkVLR  Lys1  32.6  0.8 
IKKa 
Inhibitor of nuclear factor kappa‐B kinase 
alpha subunit [Homo sapiens (Human)]  DLkPENIVLQDVGGK  Lys2  8.5  10.8 
IKKb 
Inhibitor of nuclear factor kappa B kinase beta 
subunit [Homo sapiens (Human)]  DLkPENIVLQQGEQR  Lys2  ‐13.4  ‐6.4 
IKKe,TBK1 
Inhibitor of nuclear factor kappa‐B kinase 
epsilon subunit [Homo sapiens (Human)]  DIkPGNIMR  Lys2  ‐6.7  ‐9.7 
ILK 
Integrin‐linked protein kinase 1 [Homo 









[Homo sapiens (Human)]  AIQFLHQDSPSLIHGDIkSSNVLLDER  Lys2  ‐2.2  ‐2.4 
IRAK4 
Interleukin‐1 receptor‐associated kinase 4 
[Homo sapiens (Human)]  GYVNNTTVAVkK  Lys1  ‐14.3  22.5 
IRAK4 
Interleukin‐1 receptor‐associated kinase 4 
[Homo sapiens (Human)]  DIkSANILLDEAFTAK  Lys2  ‐23.6  ‐7.7 
IRE1 
Endoribonuclease n=1 Tax=Homo sapiens 

























sapiens (Human)]  DLkPSNIVVK  Lys2  9.6  ‐7 
KHS1 
Mitogen‐activated protein kinase kinase 
kinase kinase 5 [Homo sapiens (Human)]  NVHTGELAAVkIIK  Lys1  ‐6.4  ‐7.4 
KHS2 
Mitogen‐activated protein kinase kinase 





sapiens (Human)]  ALYATkTLR  Lys1  ‐30.5  ‐8 
LATS2 
Serine/threonine‐protein kinase LATS2 n=1 
Tax=Homo sapiens RepID=LATS2_HUMAN  VDTHALYAMkTLR  Lys1  11.4  6.1 
LATS2 
Serine/threonine‐protein kinase LATS2 n=1 
Tax=Homo sapiens RepID=LATS2_HUMAN  DIkPDNILIDLDGHIK  Lys2  ‐0.2  ‐3.7 
LKB1 
Serine/threonine‐protein kinase 11 [Homo 





KPGNLLLTTGGTLK  Lys2  ‐8.8  25.7 
LOK 
Serine/threonine‐protein kinase 10 [Homo 
sapiens (Human)]  NKETGALAAAkVIETK  Lys1  7.4  9.5 
LOK 
Serine/threonine‐protein kinase 10 [Homo 
sapiens (Human)]  DLkAGNVLMTLEGDIR  Lys2  ‐9.3  ‐7.7 
LYN 
Tyrosine‐protein kinase Lyn n=1 Tax=Homo 















kinase kinase 3 [Homo sapiens (Human)]  HAQSGTIMAVkR  Lys1  ‐4  ‐7.2 
MAP2K3 
Dual specificity mitogen‐activated protein 








kinase kinase 4 [Homo sapiens (Human)]  MVHKPSGQIMAVkR  Lys1  ‐13  ‐16.1 
MAP2K4 
Dual specificity mitogen‐activated protein 














kinase kinase 6 [Homo sapiens (Human)]  HVPSGQIMAVkR  Lys1  0.1  ‐8 
MAP2K6 
Dual specificity mitogen‐activated protein 



















RepID=M3K3_HUMAN  ELASkQVQFDPDSPETSKEVSALECEIQLLK  Lys1  ‐12.9  ‐13.5 
MAP3K4 
Mitogen‐activated protein kinase kinase 
kinase 4 [Homo sapiens (Human)]  VYTCISVDTGELMAMkEIR  Lys1  ‐6.6  1.4 
MAP3K4 
Mitogen‐activated protein kinase kinase 
kinase 4 [Homo sapiens (Human)]  DIkGANIFLTSSGLIK  Lys2  ‐29.3  ‐7.7 
MAP3K5 
Mitogen‐activated protein kinase kinase 









kinase 7 [Homo sapiens (Human)]  DLkPPNLLLVAGGTVLK  Lys2  ‐6.3  ‐10.3 










[Homo sapiens (Human)]  DLkAENLLLDADMNIK  Lys2  ‐26.2  ‐16.4 
MARK3 
MAP/microtubule affinity‐regulating kinase 3 












protein kinase 2 [Homo sapiens (Human)]  DLkPDNLLVTSMGHIK  Lys2  ‐5.1  0.9 
MAST3 
Microtubule‐associated serine/threonine‐
protein kinase 3 [Homo sapiens (Human)]  DLkPDNLLITSLGHIK  Lys2  ‐8.5  ‐6.1 
MASTL 
Microtubule‐associated serine/threonine‐


























kinase 11 [Homo sapiens (Human)]  DLkSNNILLLQPIESDDMEHK  Lys2  3.9  4.1 
MLK4 
Mitogen‐activated protein kinase kinase 
kinase [Homo sapiens (Human)]  DLkSSNILLLEK  Lys2  14.6  ‐6 
MLKL 
CDNA FLJ34389 fis, clone HCHON2000087 
[Homo sapiens (Human)]  APVAIkVFK  Lys1  ‐10.7  ‐9.3 
MPSK1 
Serine/threonine‐protein kinase 16 n=1 






























sapiens (Human)]  DLkLENVLLDSEGHIVLTDFGLSK  Lys2  7.3  2.6 
MST1 
Serine/threonine‐protein kinase 4 [Homo 




sapiens (Human)]  DIkAGNILLNTEGHAK  Lys2  ‐3  ‐2.4 
MST2 
Serine/threonine‐protein kinase 3 [Homo 





SPYVVK  Lys1  ‐32  ‐8.3 
MST3 
Serine/threonine‐protein kinase 24 [Homo 











sapiens (Human)]  DIkAANVLLSEQGDVK  Lys2  ‐30.2  ‐15.5 
NDR1 
Serine/threonine‐protein kinase 38 [Homo 
sapiens (Human)]  DTGHVYAMkILR  Lys1  ‐9.4  ‐10.8 
NDR2 
Serine/threonine‐protein kinase 38‐like 
[Homo sapiens (Human)]  DTGHIYAMkILR  Lys1  4.2  ‐6.5 
NDR2 
Serine/threonine‐protein kinase 38‐like 
[Homo sapiens (Human)]  DIkPDNLLLDAK  Lys2  ‐11.8  ‐8 
NEK1 
Serine/threonine‐protein kinase Nek1 [Homo 












sapiens (Human)]  DIkPANVFITATGVVK  Lys2  6.1  ‐4.4 
NEK7 
Serine/threonine‐protein kinase Nek7 [Homo 
sapiens (Human)]  AACLLDGVPVALkK  Lys1  ‐1  ‐6 
NEK8 
Serine/threonine‐protein kinase Nek8 [Homo 








Tax=Homo sapiens RepID=NEK9_HUMAN  TEDDSLVVWkEVDLTR  Lys1  ‐9.3  5 
NEK9 
Serine/threonine‐protein kinase Nek9 n=1 





DITR  Lys2  ‐6.6  ‐9 
p38a 
Mitogen‐activated protein kinase 14 n=3 
Tax=Eutheria RepID=MK14_HUMAN  DLkPSNLAVNEDCELK  Lys2  16.5  6.3 
p38a 
Mitogen‐activated protein kinase 14 n=3 
Tax=Eutheria RepID=MK14_HUMAN  QELNkTIWEVPER  Other  ‐2.1  ‐5.7 
p38b 
Mitogen‐activated protein kinase 11 n=2 
Tax=Homo sapiens RepID=MK11_HUMAN  QELNkTVWEVPQR  Other  ‐9.6  ‐9.7 
p38d,p38g 
Mitogen‐activated protein kinase 12 [Homo 




















alpha) [Homo sapiens (Human)]  GGYGkVFQVR  ATP Loop  ‐2.3  0.8 
PCTAIRE1 
Serine/threonine‐protein kinase PCTAIRE‐1 
[Homo sapiens (Human)]  LTDNLVALkEIR  Lys1  ‐2.7  2.9 
PCTAIRE2 
Serine/threonine‐protein kinase PCTAIRE‐2 








sapiens (Human)]  SPGQPIQVVYVPSHLYHMVFELFkNAMR  Other  31.4  16.9 
PDK1 
3‐phosphoinositide‐dependent protein kinase 
1 [Homo sapiens (Human)]  EYAIkILEK  Lys1  ‐5.3  ‐11.8 
PEK 
Eukaryotic translation initiation factor 2‐alpha 
kinase 3 precursor [Homo sapiens (Human)]  DLkPSNIFFTMDDVVK  Lys2  ‐7.4  ‐3.9 


















Tax=Homo sapiens RepID=PI4KA_HUMAN  SGTPMQSAAkAPYLAK  ATP  ‐7.4  ‐3.1 
PI4KB 
Phosphatidylinositol 4‐kinase beta n=2 









sapiens]  VIFkCGDDLRQDMLTLQMIR  ATP  52.1  40.3 
PIK3C3 
Phosphatidylinositol 3‐kinase catalytic subunit 


















































(PtdIns(4)P‐5‐kinase) [Homo sapiens (Human)]  GGkSGAAFYATEDDRFILK  ATP  96.6  ‐7.7 
PITSLRE 
PITSLRE serine/threonine‐protein kinase 




sapiens RepID=KPCA_HUMAN  DLkLDNVMLDSEGHIK  Lys2  ‐0.1  ‐1.9 
PKCi 
Protein kinase C iota type [Homo sapiens 
(Human)]  IYAMkVVK  Lys1  ‐13.3  ‐0.4 
PKCz 
Protein kinase C zeta type [Homo sapiens 
(Human)]  NDQIYAMkVVK  Lys1  19.7  17.3 







Tax=Homo sapiens RepID=KPCD1_HUMAN  NIVHCDLkPENVLLASADPFPQVK  Lys2  ‐10.6  5.2 
PKD2  Protein kinase D2 [Homo sapiens (Human)] DVAVkVIDK Lys1  ‐4.3 ‐7.2
PKD3  Protein kinase D3 [Homo sapiens (Human)] NIVHCDLkPENVLLASAEPFPQVK Lys2  ‐8.9 2.8
PKN1  Protein kinase N1 [Homo sapiens (Human)] VLLSEFRPSGELFAIkALK Lys1  0.9  1.6




(Human)]  DLkPSNIFLVDTK  Lys2  ‐0.3  ‐5.4 
PLK1 
Serine/threonine‐protein kinase PLK1 [Homo 
sapiens (Human)]  CFEISDADTKEVFAGkIVPK  Lys1  ‐11.4  ‐1.5 
PLK1 
Serine/threonine‐protein kinase PLK1 [Homo 
sapiens (Human)]  DLkLGNLFLNEDLEVK  Lys2  ‐15.2  ‐7.2 
PRP4 
Serine/threonine‐protein kinase PRP4 
homolog [Homo sapiens (Human)]  CNILHADIkPDNILVNESK  Lys2  ‐1.8  ‐6.7 
PRPK 
TP53‐regulating kinase [Homo sapiens 
(Human)]  FLSGLELVkQGAEAR  ATP Loop  3.2  0.3 
RIPK2 
Receptor‐interacting serine/threonine‐protein 





DNEFHVK  Lys2  8.8  5.3 
ROCK1 
Rho‐associated protein kinase 1 [Homo 
























sapiens (Human)]  DLkPENILLDEEGHIK  Lys2  8.4  ‐2 
RSK1,RSK3 
Ribosomal protein S6 kinase alpha 1 [Homo 

































sapiens (Human)]  FYAVkVLQK  Lys1  ‐7.6  ‐9 
SLK 
CTCL tumor antigen se20‐9 [Homo sapiens 
(Human)]  ETSVLAAAkVIDTK  Lys1  ‐11.1  ‐1.8 
SLK 
CTCL tumor antigen se20‐9 [Homo sapiens 
(Human)]  DLkAGNILFTLDGDIK  Lys2  ‐9.2  ‐8.1 
SMG1 
Serine/threonine‐protein kinase SMG1 n=4 
Tax=Homo sapiens RepID=SMG1_HUMAN  DTVTIHSVGGTITILPTKTkPK  ATP  ‐5.7  ‐7.5 






n=1 Tax=Homo sapiens RepID=SRC_HUMAN  VAIkTLKPGTMSPEAFLQEAQVMK  Lys1  ‐15.5  ‐13.5 
SRPK1 
Serine/threonine‐protein kinase SRPK1 n=1 












(Human)]  SVkASHILISVDGK  Lys2  ‐32.7  ‐5.5 
STLK6 
Serine/threonine‐protein kinase ALS2CR2 
[Homo sapiens (Human)]  HTPTGTLVTIkITNLENCNEER  Lys1  0.6  ‐13.2 
STLK6 
Serine/threonine‐protein kinase ALS2CR2 




sapiens (Human)]  DIkAGNILLTEPGQVK  Lys2  ‐7  ‐11.1 
TAO2 
Serine/threonine‐protein kinase TAO2 n=2 
Tax=Homo sapiens RepID=TAOK2_HUMAN  DVkAGNILLSEPGLVK  Lys2  ‐6.8  ‐2.6 
TBK1 
Serine/threonine‐protein kinase TBK1 [Homo 
sapiens (Human)]  TGDLFAIkVFNNISFLRPVDVQMR  Lys1  ‐11.4  3.3 
TLK1 
Serine/threonine‐protein kinase tousled‐like 1 
[Homo sapiens (Human)]  YAAVkIHQLNK  Lys1  ‐28.7  ‐24.9 
TLK1,TLK2 
Serine/threonine‐protein kinase tousled‐like 1
[Homo sapiens (Human)]  YLNEIKPPIIHYDLkPGNILLVDGTACGEIK  Lys2  0.3  ‐4.7 
TLK2 
Serine/threonine‐protein kinase tousled‐like 2 
[Homo sapiens (Human)]  YVAVkIHQLNK  Lys1  ‐7.5  ‐6.8 
ULK1 
Serine/threonine‐protein kinase ULK1 [Homo 
sapiens]  DLkPQNILLSNPAGR  Lys2  ‐8.3  ‐9 
ULK3  Unc‐51‐like kinase 3 [Homo sapiens (Human)] EVVAIKCVAk Lys1  ‐11.6 0.5













sapiens (Human)]  DLkCDNVFITGPTGSVK  Lys2  ‐16.7  ‐7.1 
YANK3  PKE protein kinase [Homo sapiens (Human)] DVkPDNILLDER Lys2  13.6 ‐7.6
YES 
Proto‐oncogene tyrosine‐protein kinase Yes 





YITR  Lys1  3.5  34.6 
ZAK 
Mitogen‐activated protein kinase kinase 
kinase MLT [Homo sapiens (Human)]  WISQDKEVAVKk  Lys1  ‐3.3  ‐6.3 
ZC1/HGK 
Mitogen‐activated protein kinase kinase 
kinase kinase 4 [Homo sapiens (Human)]  TGQLAAIkVMDVTEDEEEEIKLEINMLK  Lys1  17.4  43.7 
ZC1/HGK 
Mitogen‐activated protein kinase kinase 





kinase kinase 4 [Homo sapiens (Human)]  DIkGQNVLLTENAEVK  Lys2  ‐11.4  ‐15.8 
ZC2/TNIK 
TRAF2 and NCK‐interacting kinase [Homo 
sapiens (Human)]  TGQLAAIkVMDVTGDEEEEIKQEINMLKK  Lys1  3.5  ‐8 
 
General experimental section 
All reagents were used as received. Acetonitrile, DCM, toluene and THF were purified using the 
Innovative Technology PureSolv solvent purification system. The 1H and 13C spectra were recorded on a 
Bruker Avance 400 or 500 MHz spectrometer. Chemical shifts are reported in parts per million and were 
referenced to residual proton solvent signals. Flash column chromatography separations were performed 
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using the Teledyne Isco CombiFlash Rf using RediSep Rf silica gel columns. TLC was performed on 
Analtech UNIPLATE silica gel GHLF plates (gypsum inorganic hard layer with fluorescence). TLC 
plates were developed using iodine vapor. Automated preparative RP HPLC purification was performed 
using an Agilent 1200 Mass-Directed Fractionation system (Prep Pump G1361 with gradient extension, 
Make-up pump G1311A, pH modification pump G1311A, HTS PAL autosampler, UV-DAD detection 
G1315D, Fraction Collector G1364B, and Agilent 6120 quadrapole spectrometer G6120A). The 
preparative chromatography conditions included a Waters X-Bridge C18 column (19 × 150 mm, 5 um, 
with 19 × 10-mm guard column), elution with a water and acetonitrile gradient, which increases 20% in 
acetonitrile content over 4 min at a flow rate of 20 mL/min (modified to pH 9.8 through addition of 
NH4OH by auxiliary pump), and sample dilution in DMSO. The preparative gradient, triggering 
thresholds, and UV wavelength were selected according to the analytical RP HPLC analysis of each crude 
sample. The analytical method used an Agilent 1200 RRLC system with UV detection (Agilent 1200 
DAD SL) and mass detection (Agilent 6224 TOF). The analytical method conditions included a Waters 
Aquity BEH C18 column (2.1 × 50 mm, 1.7 um) and elution with a linear gradient of 5% acetonitrile in 
pH 9.8 buffered aqueous ammonium formate to 100% acetonitrile at 0.4 mL/min flow rate. Compound 
purity was measured on the basis of peak integration (area under the curve) from UV/vis absorbance (at 
214 nm), and compound identity was determined on the basis of mass analysis.  
Compounds S1-S44 and S57-S69 were purchased from commercial vendors. All synthetic compounds 
were synthesized by one of four general synthetic methods (A to D) described below. The yield, purity 
and characterization of compounds synthesized by each method are compiled immediately following each 
method. 
General Procedure A: Representative protocol for the synthesis of quinazoline analogues, 
synthesis and characterization for 16, S45-S56, S70-S125, S142-S147, S156-S160, ML241, S162, 
S165, S169-S188. 
 
Scheme S1: General synthesis of 2,4-diaminoquinazolines 
 
Representative procedure for the synthesis of quinazoline analogues: 
 
KSC-206-026   
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N-Benzyl-2-chloroquinazolin-4-amine. 2,4-dichloroquinazoline (2.4 g, 12.3 mmol) was 
suspended in 20 mL of THF. Triethylamine (2.1 mL, 14.7 mmol) was added, followed by the 
addition of benzylamine (1.4 mL, 12.9 mmol). The mixture was stirred at room temperature for 
16 h. The mixture was diluted with EtOAc, filtered, and the filtrate was concentrated. The 
residue was purified by silica gel chromatography (EtOAc:hexanes = 1:3, Rf = 0.5) to give a 
colorless solid (1.6 g, 47%). 1H NMR (400MHz, CDCl3) δ 7.87–7.73 (m, 2H), 7.68 (d, J = 8.2 
Hz, 1H), 7.54–7.32 (m, 6H), 6.10 (s, 1H), 4.90 (d, J = 5.3 Hz, 2H). 
 
 2-(2-Amino-1H-benzo[d]imidazol-1-yl)-N-benzylquinazolin-4-amine (16). A suspension of 
N-benzyl-2-chloroquinazolin-4-amine (0.015 g, 0.056 mmol) and 1H-benzo[d]imidazol-2-amine 
(0.015 g, 0.111 mmol) in Acetonitrile (1 ml) was heated in microwave at 180 °C for 1 h. Solvent 
was removed and the crude sample was purified via reverse phase preparative HPLC. Yield: 6.8 
mg, 33%.1H NMR (400 MHz, DMSO) δ 9.42 (t, J = 5.8 Hz, 1H), 8.41 (d, J = 8.1 Hz, 1H), 8.12 
(d, J = 7.5 Hz, 1H), 7.94 – 7.79 (m, 4H), 7.54 – 7.50 (m, 1H), 7.45 (d, J = 7.1 Hz, 2H), 7.37 (t, J 
= 7.6 Hz, 2H), 7.27 (t, J = 7.3 Hz, 1H), 7.15 (d, J = 7.1 Hz, 1H), 7.03 (td, J = 1.2, 7.6 Hz, 1H), 
6.88 – 6.76 (m, 1H), 4.91 (d, J = 5.8 Hz, 2H). 13C NMR (126 MHz, DMSO) δ 160.7, 154.5, 
154.1, 148.9, 142.8, 138.4, 133.7, 131.7, 128.5, 127.0, 126.6, 125.1, 123.0, 122.5, 118.7, 114.8, 









4,4'-(Quinazoline-2,4-diyl)bis(3,4-dihydro-2H-benzo[b][1,4]oxazine) (S45). Yield: 10.4 mg, 
33%. 1H NMR (400 MHz, CDCl3) δ 8.03 (dd, J = 1.5, 8.2 Hz, 1H), 7.66 (dd, J = 0.8, 8.4 Hz, 1H), 
7.59 (dd, J = 0.8, 8.5 Hz, 1H), 7.53 (ddd, J = 1.4, 6.7, 8.4 Hz, 1H), 7.00 (ddd, J = 1.4, 6.7, 8.2 Hz, 
1H), 6.96 – 6.75 (m, 5H), 6.71 (d, J = 8.1 Hz, 1H), 6.67 – 6.53 (m, 1H), 4.48 – 4.36 (m, 2H), 
4.36 – 4.22 (m, 4H), 4.07 – 3.95 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 161.4, 156.4, 154.0, 
146.4, 145.7, 133.3, 129.7, 127.7, 127.0, 126.2, 124.3, 124.0, 123.8, 122.2, 120.4, 120.0, 119.5, 
117.3, 117.0, 113.7, 66.5, 66.1, 45.6, 42.3. HRMS (m/z): calcd for C24H21N4O2 (M+H) 397.1665; 






1-(4-(4-(Benzylamino)-8-methoxyquinazolin-2-yl)piperazin-1-yl)ethanone (S46). Yield: 20.6 
mg, 79%. 1H NMR (400 MHz, CDCl3) δ 7.43 – 7.34 (m, 4H), 7.34 – 7.29 (m, 1H), 7.16 (dd, J = 
1.3, 8.2 Hz, 1H), 7.05 (t, J = 7.9 Hz, 1H), 6.99 (dd, J = 1.2, 7.8 Hz, 1H), 5.97 (t, J = 5.3 Hz, 1H), 
4.81 (d, J = 5.4 Hz, 2H), 3.99 (s, 3H), 3.98 – 3.94 (m, 2H), 3.91 (dd, J = 4.3, 6.3 Hz, 2H), 3.74 – 
3.63 (m, 2H), 3.58 – 3.46 (m, 2H), 2.15 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 169.2, 159.8, 
158.4, 153.4, 143.9, 138.7, 128.7, 127.8, 127.5, 121.0, 112.6, 111.2, 111.0, 56.1, 46.4, 45.4, 44.0, 






N2,N4-Dibenzyl-8-methoxy-N2-methylquinazoline-2,4-diamine (S47). Yield: 21.8 mg, 85%. 
1H NMR (400 MHz, CDCl3) δ 7.40 – 7.19 (m, 10H), 7.12 (dd, J = 2.0, 7.3 Hz, 1H), 7.07 – 6.93 
(m, 2H), 5.81 (s, 1H), 5.02 (s, 2H), 4.75 (d, J = 5.5 Hz, 2H), 4.00 (s, 3H), 3.28 (s, 3H). 13C NMR 
(101 MHz, CDCl3) δ 159.6, 159.1, 153.4, 139.4, 138.9, 128.7, 128.3, 127.9, 127.5, 127.4, 126.7, 
120.1, 112.5, 111.1, 110.6, 56.1, 52.5, 45.2, 34.7. HRMS (m/z): calcd for C24H25N4O (M+H) 






N-Benzyl-8-methoxy-2-morpholinoquinazolin-4-amine (S48). Yield: 14.2 mg, 81%. 1H NMR 
(400 MHz, DMSO) δ 8.52 (t, J = 5.7 Hz, 1H), 7.63 (dd, J = 1.9, 7.6 Hz, 1H), 7.41 – 7.35 (m, 2H), 
7.35 – 7.28 (m, 2H), 7.26 – 7.18 (m, 1H), 7.08 – 6.98 (m, 2H), 4.70 (d, J = 5.8 Hz, 2H), 3.83 (s, 
3H), 3.74 – 3.66 (m, 4H), 3.64 – 3.54 (m, 4H). 13C NMR (101 MHz, DMSO) δ 159.7, 157.9, 
152.9, 143.4, 140.0, 128.2, 127.3, 126.6, 120.3, 114.2, 112.0, 111.0, 66.1, 55.5, 44.2, 43.7. 





N-Benzyl-8-methoxy-2-(4-methylpiperazin-1-yl)quinazolin-4-amine (S49). Yield: 12.0 mg, 
66%. 1H NMR (500 MHz, DMSO) δ 8.47 (t, J = 5.9 Hz, 1H), 7.60 (dd, J = 1.4, 8.0 Hz, 1H), 7.37 
(d, J = 7.1 Hz, 2H), 7.30 (dd, J = 4.8, 10.3 Hz, 2H), 7.21 (t, J = 7.3 Hz, 1H), 7.03 (dd, J = 1.3, 
7.8 Hz, 1H), 6.99 (t, J = 7.8 Hz, 1H), 4.68 (d, J = 5.8 Hz, 2H), 3.82 (s, 3H), 3.71 (s, 4H), 2.27 (t, 
J = 4.9 Hz, 4H), 2.17 (s, 3H). 13C NMR (126 MHz, DMSO) δ 159.6, 157.8, 152.8, 143.6, 140.1, 
128.1, 127.3, 126.6, 120.0, 114.1, 111.8, 110.8, 55.5, 54.6, 45.9, 43.7, 43.3. HRMS (m/z): calcd 






N2,N4-Bis(4-methoxyphenyl)quinazoline-2,4-diamine (S50). Yield: 11.9 mg, 91%.  1H NMR 
(400 MHz, CDCl3) δ 7.71 (d, J = 8.0 Hz, 1H), 7.68 – 7.52 (m, 6H), 7.29 (s, br. 1H), 7.24 (ddd, J 
= 1.7, 6.5, 8.2 Hz, 1H), 7.08 – 6.92 (m, 3H), 6.93 – 6.83 (m, 2H), 3.87 (s, 3H), 3.83 (s, 3H). 13C 
NMR (101 MHz, CDCl3) δ 158.4, 156.9, 156.7, 155.1, 152.0, 133.3, 133.0, 131.3, 126.5, 124.2, 
122.2, 121.5, 120.5, 114.2, 114.0, 111.4, 55.58, 55.56. HRMS (m/z): calcd for C22H21N4O2 







N2-(3-Chlorophenyl)-N4-phenylquinazoline-2,4-diamine (S51). Yield: 13.0 mg, 96%. 1H 
NMR (400 MHz, CDCl3) δ 7.88 (t, J = 2.0 Hz, 1H), 7.71 – 7.53 (m, 5H), 7.37 (dd, J = 5.2, 10.7 
Hz, 3H), 7.31 (s, br. 1H), 7.22 (ddd, J = 2.9, 5.3, 8.2 Hz, 1H), 7.17 – 7.00 (m, 3H), 6.89 (ddd, J = 
0.9, 2.0, 7.9 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 158.2, 156.1, 151.8, 141.3, 138.1, 134.5, 
133.3, 129.7, 129.2, 126.9, 124.7, 123.1, 122.1, 121.9, 120.5, 119.1, 117.1, 111.7.  HRMS (m/z): 






N2-(3-Chlorophenyl)-N4-(4-methoxyphenyl)quinazoline-2,4-diamine (S52). Yield: 13.0 mg, 
99%. 1H NMR (400 MHz, CDCl3) δ 1H NMR (400 MHz, CDCl3) δ 7.85 (t, J = 2.0 Hz, 1H), 7.63 
(d, J = 8.0 Hz, 1H), 7.61 – 7.52 (m, 2H), 7.49 – 7.39 (m, 2H), 7.31 – 7.11 (m, 4H), 7.08 (t, J = 
8.1 Hz, 1H), 6.94 – 6.80 (m, 3H), 3.77 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 158.8, 157.1, 
156.2, 151.6, 141.4, 134.4, 133.3, 130.8, 129.6, 126.7, 124.6, 122.9, 121.7, 120.6, 118.9, 117.0, 
114.4, 111.6, 55.6. HRMS (m/z): calcd for C21H18ClN4O (M+H) 377.1169; found 377.1169.  
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0






N2-(3-Chlorophenyl)-N4-(p-tolyl)quinazoline-2,4-diamine (S53). Yield: 5.7 mg, 69%. 1H 
NMR (400 MHz, CDCl3) δ 7.89 (t, J = 2.0 Hz, 1H), 7.66 (d, J = 8.1 Hz, 1H), 7.60 (dd, J = 1.6, 
5.1 Hz, 2H), 7.47 (d, J = 8.4 Hz, 2H), 7.38 – 7.30 (m, 1H), 7.22 (ddd, J = 4.7, 7.4, 8.2 Hz, 2H), 
7.16 (s, br. 2H), 7.12 (t, J = 8.1 Hz, 2H), 6.89 (ddd, J = 0.9, 2.0, 7.9 Hz, 1H), 2.32 (s, 3H). 13C 
NMR (101 MHz, CDCl3) δ 158.5, 156.1, 151.7, 141.4, 135.3, 134.6, 134.5, 133.3, 129.7, 129.6, 
126.8, 123.0, 122.5, 121.8, 120.5, 119.0, 117.0, 111.7, 21.0. HRMS (m/z): calcd for C21H18ClN4 
(M+H) 361.1220; found 361.1228.  
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)  
-100102030405060708090100110120130140150160170180190200210




N2-(3-Chlorophenyl)-N4-(4-chlorophenyl)quinazoline-2,4-diamine (S54). Yield: 13.0 mg, 
99%. 1H NMR (400 MHz, CDCl3) δ 7.97 (t, J = 2.0 Hz, 1H), 7.78 – 7.61 (m, 5H), 7.46 – 7.36 (m, 
4H), 7.32 (ddd, J = 2.1, 6.1, 8.2 Hz, 1H), 7.23 (t, J = 8.0 Hz, 2H), 7.01 (ddd, J = 0.9, 2.0, 7.9 Hz, 
1H).  13C NMR (101 MHz, CDCl3) δ 158.1, 156.0, 151.8, 141.2, 136.6, 134.5, 133.5, 129.7, 
129.7, 129.2, 126.9, 123.4, 123.2, 122.1, 120.4, 119.2, 117.2, 111.5. HRMS (m/z): calcd for 


















N2,N4-Di-p-tolylquinazoline-2,4-diamine (S55). Yield: 37.8 mg, 44%. 1H NMR (400 MHz, 
CDCl3) δ 7.70 (t, J = 8.0 Hz, 1H), 7.66 (dd, J = 3.8, 4.5 Hz, 2H), 7.64 – 7.56 (m, 4H), 7.39 (s, br. 
1H), 7.28 – 7.19 (m, 3H), 7.14 (d, J = 8.1 Hz, 2H), 7.08 (s, br. 1H), 2.42 (s, 3H), 2.37 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 158.3, 156.8, 152.1, 137.6, 135.7, 134.1, 133.0, 131.5, 129.5, 
129.3, 126.7, 122.3, 122.3, 120.6, 119.7, 111.6, 21.0, 20.9. HRMS (m/z): calcd for C22H21N4 
(M+H) 341.1766; found 341.1759.  
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)  
-100102030405060708090100110120130140150160170180190200210




N2,N4-Diphenylquinazoline-2,4-diamine (S56). Yield: 11.8 mg, 97%. 1H NMR (400 MHz, 
CDCl3) δ 7.79 – 7.71 (m, 6H), 7.71 – 7.65 (m, 2H), 7.48 – 7.42 (m, 2H), 7.40 (s, br. 1H), 7.38 – 
7.29 (m, 3H), 7.26 – 7.20 (m, 1H), 7.17 (s, br. 1H), 7.09 – 7.00 (m, 1H). 13C NMR (101 MHz, 
CDCl3) δ 158.2, 156.5, 152.0, 140.0, 138.3, 133.2, 129.0, 128.8, 126.8, 124.5, 122.7, 122.1, 







N4-Benzyl-N2-(4-methoxyphenyl)quinazoline-2,4-diamine (S70). Yield: 32.0 mg, 48%. 1H 
NMR (400 MHz, CDCl3) δ 7.66 – 7.58 (m, 4H), 7.56 (d, J = 8.2 Hz, 1H), 7.46 – 7.39 (m, 4H), 
7.37 – 7.33  (m, 1H), 7.16 (ddd, J = 2.3, 5.8, 8.2 Hz, 1H), 7.02 (s, br. 1H), 6.93 – 6.81 (m, 2H), 
5.95 (s, br. 1H), 4.84 (d, J = 5.3 Hz, 2H), 3.82 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 160.1, 
157.2, 154.9, 151.8, 138.4, 133.6, 132.9, 128.8, 127.9, 127.6, 126.3, 121.9, 121.2, 120.7, 114.0, 



























N4-Benzyl-N2-(3-bromophenyl)quinazoline-2,4-diamine (S71). Yield: 47.0 mg, 63%. 1H NMR 
(400 MHz, CDCl3) δ 8.21 (t, J = 1.9 Hz, 1H), 7.64 (t, J = 6.5 Hz, 2H), 7.58 (d, J = 8.2 Hz, 1H), 
7.55 – 7.49 (m, 1H), 7.48 – 7.33 (m, 5H), 7.27 – 7.06 (m, 4H), 5.93 (t, J = 5.4 Hz, 1H), 4.88 (d, J 
= 5.4 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 160.1, 156.5, 151.4, 141.8, 138.2, 133.0, 130.0, 
128.9, 127.9, 127.8, 126.6, 124.4, 122.6, 122.6, 121.7, 120.7, 117.3, 111.6, 45.4. HRMS (m/z): 




























N4-Benzyl-N2-(3-methoxyphenyl)quinazoline-2,4-diamine (S72). Yield: 64.0 mg, 97%. 1H 
NMR (400 MHz, CDCl3) δ 7.70 – 7.59 (m, 3H), 7.56 (d, J = 8.0 Hz, 1H), 7.46 – 7.30 (m, 6H), 
7.25 – 7.13 (m, 3H), 6.59 (ddd, J = 1.6, 2.4, 7.6 Hz, 1H), 6.01 (t, J = 5.3 Hz, 1H), 4.87 (d, J = 5.4 
Hz, 2H), 3.81 (s, 3H).  13C NMR (101 MHz, CDCl3) δ 160.2, 160.2, 156.9, 151.6, 141.7, 138.4, 
132.9, 129.4, 128.9, 127.9, 127.7, 126.5, 122.3, 120.8, 111.50, 111.47, 107.5, 104.7, 55.2, 45.3. 






















N4-Benzyl-N2-(3-nitrophenyl)quinazoline-2,4-diamine (S73). Yield: 11.0 mg, 80%.  1H NMR 
(400 MHz, CDCl3) δ 9.03 (t, J = 2.2 Hz, 1H), 7.82 – 7.68 (m, 2H), 7.62 (d, J = 3.6 Hz, 2H), 7.56 
(d, J = 8.2 Hz, 1H), 7.45 (s, br. 1H), 7.42 – 7.26 (m, 6H), 7.20 (dd, J = 3.9, 8.0 Hz, 1H), 5.94 (s, 
1H), 4.87 (d, J = 5.2 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 160.2, 156.3, 151.0, 148.8, 141.6, 
137.9, 133.3, 129.3, 128.9, 127.9, 127.9, 126.6, 124.1, 123.0, 120.7, 116.1, 113.4, 111.6, 45.6, 







N4-Benzyl-N2-(3-fluorophenyl)quinazoline-2,4-diamine (S74 or 44). Yield: 58.0 mg, 91%. 1H 
NMR (400 MHz, CDCl3) δ 8.00 – 7.87 (m, 1H), 7.71 – 7.61 (m, 2H), 7.58 (d, J = 8.1, 1H), 7.50 
– 7.33 (m, 5H), 7.29 – 7.12 (m, 4H), 6.78 – 6.62 (m, 1H), 5.97 (s, br. 1H), 4.87 (d, J = 5.3 Hz, 
2H). 13C NMR (101 MHz, CDCl3) δ 164.5, 162.1, 160.1, 156.5, 151.4, 142.2, 142.1, 138.2, 
133.0, 129.7, 129.6, 128.89, 127.87, 127.8, 126.6, 122.6, 120.7, 114.12, 114.09, 111.6, 108.2, 
108.0, 106.2, 105.9, 45.4. HRMS (m/z): calcd for C21H18FN4 (M+H) 345.1515; found 345.1510.  
  
-100102030405060708090100110120130140150160170180190200210




N4-Benzyl-N2-(5-chloro-2-fluorophenyl)quinazoline-2,4-diamine (S75). Yield: 58.0 mg, 83%. 
1H NMR (400 MHz, CDCl3) δ 9.00 (dd, J = 2.6, 7.3 Hz, 1H), 7.77 – 7.62 (m, 2H), 7.59 (d, J = 
8.0 Hz, 1H), 7.52 – 7.32 (m, 5H), 7.25 – 7.23 (m, 1H), 7.21 (s, br. 1H), 7.03 (dd, J = 8.7, 11.0 Hz, 
1H), 6.89 (ddd, J = 2.6, 4.3, 8.6 Hz, 1H), 5.93 (s, br. 1H), 4.88 (t, J = 7.5 Hz, 2H). 13C NMR 
(101 MHz, CDCl3) δ 160.1, 156.1, 151.7, 151.2, 149.3, 138.1, 133.1, 130.1, 130.0, 129.4, 129.3, 
128.9, 128.0, 127.8, 126.8, 123.0, 120.7, 120.53, 120.45, 120.0, 115.3, 115.1, 111.7, 45.5. 








N4-Benzyl-N2-(3,5-dichlorophenyl)quinazoline-2,4-diamine (S76). Yield: 73.0 mg, 100%. 1H 
NMR (400 MHz, CDCl3) δ 7.75 (d, J = 1.8 Hz, 2H), 7.69 – 7.61 (m, 2H), 7.58 (d, J = 8.2 Hz, 
1H), 7.52 – 7.31 (m, 6H), 7.28 – 7.18 (m, 1H), 6.96 (t, J = 1.8 Hz, 1H), 6.00 (t, J = 5.3 Hz, 1H), 
4.86 (d, J = 5.4 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 160.2, 156.3, 151.1, 142.4, 138.0, 134.8, 
133.2, 128.9, 127.9, 127.8, 126.6, 122.9, 121.1, 120.8, 116.9, 111.6, 45.4. HRMS (m/z): calcd 





N4-Benzyl-N2-(3-chloro-2-methoxyphenyl)quinazoline-2,4-diamine (S77). Yield: 6.2 mg, 
43%. 1H NMR (400 MHz, CDCl3) δ 8.60 (s, 1H), 7.61 (dd, J = 1.2, 4.6 Hz, 2H), 7.55 (d, J = 8.1 
Hz, 1H), 7.47 – 7.28 (m, 5H), 7.23 – 7.10 (m, 1H), 6.99 (t, J = 8.1 Hz, 1H), 6.93 (dd, J = 1.7, 8.1 
Hz, 1H), 5.92 (s, br. 1H), 4.85 (d, J = 5.3 Hz, 2H), 3.91 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 
160.1, 156.4, 144.6, 138.2, 135.4, 133.1, 128.9, 127.9, 127.8, 126.9, 126.3, 124.8, 122.7, 122.2, 
120.7, 117.9, 111.5, 60.7, 45.5. HRMS (m/z): calcd for C22H20ClN4O (M+H) 391.1326; found 
391.1324.  
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0





N4-Benzyl-N2-(3-fluoro-2-methylphenyl)quinazoline-2,4-diamine (S78). Yield: 13.0 mg, 98%. 
1H NMR (400 MHz, CDCl3) δ 8.07 (d, J = 8.3 Hz, 1H), 7.66 – 7.58 (m, 3H), 7.46 – 7.31 (m, 5H), 
7.21 (ddd, J = 1.8, 6.3, 8.2 Hz, 1H), 7.15 (dd, J = 8.0, 15.0 Hz, 1H), 6.88 (s, br. 1H), 6.79 (t, J = 
8.5 Hz, 1H), 5.97 (s, br. 1H), 4.84 (d, J = 5.2 Hz, 2H), 2.27 (d, J = 1.7 Hz, 3H). 13C NMR (101 
MHz, CDCl3) δ 162.4, 160.2, 160.0, 157.1, 151.5, 139.9, 139.9, 138.3, 133.0, 128.8, 127.9, 
127.7, 126.5, 126.43, 126.36, 122.4, 120.7, 116.89, 116.86, 115.1, 115.0, 111.5, 109.3, 109.0, 
45.3, 9.32, 9.26. HRMS (m/z): calcd for C22H20FN4 (M+H) 359.1672; found 359.1677.  
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)  
-100102030405060708090100110120130140150160170180190200210




N4-Benzyl-N2-(3-fluoro-5-methylphenyl)quinazoline-2,4-diamine (S79). Yield: 13.0 mg, 98%. 
1H NMR (400 MHz, CDCl3) δ 7.64 (d, J = 11.6 Hz, 1H), 7.54 (d, J = 3.5 Hz, 2H), 7.47 (d, J = 
8.1 Hz, 1H), 7.39 – 7.21 (m, 5H), 7.15 – 6.99 (m, 2H), 6.94 (s, 1H), 6.43 (d, J = 9.3 Hz, 1H), 
5.85 (s, br. 1H), 4.77 (d, J = 5.0 Hz, 2H), 2.22 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 164.4, 
162.0, 160.1, 156.5, 151.3, 141.7, 141.6, 140.1, 140.0, 138.2, 133.0, 128.9, 127.9, 127.8, 126.5, 
122.5, 120.7, 114.74, 114.72, 111.5,  109.1, 108.9, 103.4, 103.2, 103.0, 45.4, 21.58, 21.56. 
HRMS (m/z): calcd for C22H20FN4 (M+H) 359.1672; found 359.1675.  
 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)  
-100102030405060708090100110120130140150160170180190200210




N4-Benzyl-N2-(3-fluoro-2-methoxyphenyl)quinazoline-2,4-diamine (S80). Yield: 12.4 mg, 
89%. 1H NMR (400 MHz, CDCl3) δ 8.44 (d, J = 8.4 Hz, 1H), 7.72 – 7.41 (m, 4H), 7.41 – 7.21 
(m, 5H), 7.12 (ddd, J = 2.8, 5.3, 8.2 Hz, 1H), 6.89 (td, J = 6.0, 8.4 Hz, 1H), 6.62 (ddd, J = 1.5, 
8.4, 11.2 Hz, 1H), 5.85 (s, br. 1H), 4.80 (d, J = 5.3 Hz, 2H), 3.92 (d, J = 1.6 Hz, 3H). 13C NMR 
(101 MHz, CDCl3) δ 160.1, 156.5, 156.3, 153.9, 151.2, 138.2, 136.0, 135.8, 134.9, 134.9, 133.0, 
128.9, 127.9, 127.8, 126.5, 123.5, 123.4, 122.6, 120.7, 114.3, 111.5, 108.8, 108.6,  61.5, 61.4, 

























N4-Benzyl-N2-(3-chloro-2-methylphenyl)quinazoline-2,4-diamine (S81). Yield: 11.7 mg, 84%. 
1H NMR (400 MHz, CDCl3) δ 8.02 (dd, J = 2.6, 6.7 Hz, 1H), 7.60 – 7.53 (m, 3H), 7.41 – 7.26 
(m, 5H), 7.16 (ddd, J = 1.5, 6.6, 8.2 Hz, 1H), 7.12 – 7.01 (m, 2H), 7.00 – 6.71 (s, br. 1H), 5.92 (s, 
br. 1H), 4.76 (d, J = 5.2 Hz, 2H), 2.38 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 160.2, 157.1, 
151.1, 139.5, 138.2, 134.5, 133.1, 128.8, 127.9, 127.7, 126.9, 126.5, 126.1, 123.9, 122.4, 120.8, 
120.7, 111.4, 45.3, 14.8. HRMS (m/z): calcd for C22H20ClN4 (M+H) 375.1376; found 375.1378.  
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0













N4-Benzyl-N2-(5-fluoro-2-methylphenyl)quinazoline-2,4-diamine (S82). Yield: 12.7 mg, 96%. 
1H NMR (400 MHz, CDCl3) δ 8.30 (dd, J = 2.6, 12.1 Hz, 1H), 7.54 (d, J = 3.6 Hz, 2H), 7.49 (d, 
J = 8.2 Hz, 1H), 7.39 – 7.20 (m, 5H), 7.11 (dt, J = 4.1, 8.2 Hz, 1H), 7.06 – 6.94 (m, 1H), 6.83 (s, 
br. 1H), 6.56 (td, J = 2.7, 8.2 Hz, 1H), 5.87 (s, br. 1H), 4.76 (d, J = 5.2 Hz, 2H), 2.23 (s, 3H). 13C 
NMR (101 MHz, CDCl3) δ 162.8, 160.5, 160.1, 156.6, 151.1, 139.6, 139.4, 138.1, 133.1, 130.7, 
130.6, 128.9, 128.0, 127.8, 126.4, 122.6, 121.3, 120.7, 111.5, 108.3, 108.0, 107.4, 107.1, 45.4, 
17.5. HRMS (m/z): calcd for C22H20FN4 (M+H) 359.1672; found 359.1678.  
 
-100102030405060708090100110120130140150160170180190200210











N4-Benzyl-N2-(3-fluoro-4-methylphenyl)quinazoline-2,4-diamine (S83). Yield: 13.0 mg, 98%. 
1H NMR (400 MHz, CDCl3) δ 7.78 (dd, J = 2.1, 12.4, 1H), 7.64 – 7.55 (m, 2H), 7.51 (d, J = 8.1, 
1H), 7.43 – 7.25 (m, 5H), 7.20 – 7.12 (m, 1H), 7.12 – 6.92 (m, 3H), 5.87 (s, br. 1H), 4.81 (d, J = 
5.2 Hz, 2H), 2.20 (d, J = 1.6 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 162.5, 160.11, 160.08, 
156.6, 151.4, 139.6, 139.5, 138.2, 133.0, 131.02, 130.95, 128.9, 127.9, 127.7, 126.5, 122.4, 120.7, 
117.6, 117.4, 114.14, 114.11, 111.5, 106.3, 106.1, 45.4, 14.02, 13.99. HRMS (m/z): calcd for 
C22H20FN4 (M+H) 359.1672; found 359.1673.  
0.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0





N4-Benzyl-N2-(3-fluoro-4-methoxyphenyl)quinazoline-2,4-diamine (S84). Yield: 13.0 mg, 
94%. 1H NMR (400 MHz, CDCl3) δ 7.76 (dd, J = 2.6, 13.8 Hz, 1H), 7.59 – 7.41 (m, 3H), 7.39 – 
7.20 (m, 5H), 7.16 – 7.02 (m, 2H), 6.95 (s, br. 1H), 6.81 (t, J = 9.1 Hz, 1H), 5.83 (s, br. 1H), 4.75 
(d, J = 5.2 Hz, 2H), 3.79 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 160.1, 156.7, 153.6, 151.4, 
151.2, 142.6, 142.4, 138.2, 134.4, 134.3, 133.0, 128.9, 127.9, 127.7, 126.4, 122.3, 120.7, 114.4, 
114.4, 114.1, 114.1, 111.5, 108.5, 108.3, 56.9, 45.3. HRMS (m/z): calcd for C22H20FN4O (M+H) 
375.1621; found 375.1623.  
 
-100102030405060708090100110120130140150160170180190200210











N4-Benzyl-N2-(5-chloro-2-methylphenyl)quinazoline-2,4-diamine (S85). Yield: 10.6 mg, 76%. 
1H NMR (400 MHz, CDCl3) δ 8.48 (d, J = 2.1 Hz, 1H), 7.61 – 7.44 (m, 3H), 7.38 – 7.21 (m, 5H), 
7.12 (ddd, J = 2.8, 5.3, 8.2 Hz, 1H), 7.01 (d, J = 8.1 Hz, 1H), 6.85 (dd, J = 2.2, 8.0 Hz, 2H), 5.88 
(s, br. 1H), 4.77 (d, J = 5.1 Hz, 2H), 2.24 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 160.2, 156.6, 
139.3, 138.1, 133.1, 131.8, 131.0, 128.9, 128.0, 127.8, 126.2, 124.9, 122.6, 121.9, 120.7, 120.5, 
111.5, 45.4, 17.7.  HRMS (m/z): calcd for C22H20ClN4 (M+H) 375.1376; found 375.1379.  
0.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)  
-100102030405060708090100110120130140150160170180190200210




N4-Benzyl-N2-(5-chloro-2-methoxyphenyl)quinazoline-2,4-diamine (S86). Yield: 11.0 mg, 
76%. 1H NMR (400 MHz, CDCl3) δ 8.83 (s, 1H), 7.75 – 7.41 (m, 4H), 7.41 – 7.21 (m, 5H), 7.11 
(ddd, J = 1.7, 6.5, 8.2 Hz, 1H), 6.80 (dd, J = 2.6, 8.6 Hz, 1H), 6.69 (d, J = 8.6 Hz, 1H), 5.87 (s, br. 
1H), 4.81 (d, J = 5.3 Hz, 2H), 3.81 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 160.1, 156.3, 146.3, 
138.2, 133.0, 131.0, 128.9, 128.0, 127.8, 126.4, 125.9, 122.6, 120.7, 120.2, 118.5, 111.4, 110.4, 






N4-Benzyl-N2-(5-fluoro-2-methoxyphenyl)quinazoline-2,4-diamine (S87). Yield: 13.0 mg, 
94%. 1H NMR (400 MHz, CDCl3) δ 8.75 – 8.57 (m, 1H), 7.71 – 7.52 (m, 3H), 7.40 (qdd, J = 5.5, 
8.0, 13.6 Hz, 6H), 7.18 (ddd, J = 3.3, 4.8, 8.2 Hz, 1H), 6.76 – 6.60 (m, 2H), 5.91 (s, br. 1H), 4.88 
(d, J = 5.4 Hz, 2H), 3.91 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 160.0, 158.9, 156.8, 156.5, 
151.6, 148.8, 148.7, 138.4, 132.9, 128.8, 127.9, 127.7, 126.5, 126.14, 126.11, 122.1, 120.7, 119.3, 
119.2, 111.4, 106.4, 106.1, 98.6, 98.4, 55.9, 45.4. HRMS (m/z): calcd for C22H20FN4O (M+H) 
375.1621; found 375.1622.  
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0





N4-Benzyl-N2-(2-bromophenyl)quinazoline-2,4-diamine (S88). Yield: 18.0 mg, 60%. 1H NMR 
(400 MHz, CDCl3) δ 8.67 (dd, J = 1.5, 8.3 Hz, 1H), 7.59 – 7.51 (m, 2H), 7.51 – 7.44 (m, 2H), 
7.41 (s, br. 1H), 7.37 – 7.28 (m, 4H), 7.28 – 7.19 (m, 2H), 7.13 (ddd, J = 2.3, 5.8, 8.2 Hz, 1H), 
6.81 – 6.73 (m, 1H), 5.81 (s, br. 1H), 4.78 (d, J = 5.4 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 
160.1, 156.5, 151.4, 138.3, 138.1, 132.9, 132.2, 128.9, 128.0, 127.9, 127.7, 126.7, 122.7, 122.4, 
120.7, 120.6, 112.8, 111.7, 45.4. HRMS (m/z): calcd for C21H18BrN4 (M+H) 405.0715 and 






N4-Benzyl-N2-(2-chlorophenyl)quinazoline-2,4-diamine (S89). Yield: 39.0 mg, 86%. 1H NMR 
(400 MHz, CDCl3) δ 8.82 (dd, J = 1.5, 8.4 Hz, 1H), 7.72 – 7.62 (m, 2H), 7.59 (d, J = 8.1 Hz, 1H), 
7.51 (s, br. 1H), 7.48 – 7.32 (m, 6H), 7.28 – 7.20 (m, 2H), 6.98 – 6.90 (m, 1H), 5.91 (s, br. 1H), 
4.89 (d, J = 5.4 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 160.1, 156.4, 151.4, 138.3, 137.0, 132.9, 
128.93, 128.87, 128.0, 127.7, 127.3, 126.8, 122.7, 121.9, 121.8, 120.6, 120.3, 111.7, 45.4. 
























N4-Benzyl-N2-(3-(trifluoromethyl)phenyl)quinazoline-2,4-diamine (S90). Yield: 14.6 mg, 
100%. 1H NMR (400 MHz, CDCl3) δ 8.34 (s, 1H), 7.77 (d, J = 8.2 Hz, 1H), 7.71 – 7.54 (m, 3H), 
7.54 – 7.31 (m, 7H), 7.24 (ddd, J = 2.4, 5.0, 8.2 Hz, 2H), 5.95 (s, br. 1H), 4.89 (d, J = 5.3 Hz, 
2H). 13C NMR (101 MHz, CDCl3) δ 160.2, 156.5, 151.3, 140.9, 138.0, 133.1, 131.5,  131.2, 
130.9, 130.5, 129.1, 128.9, 127.9, 127.8, 126.5, 125.7, 123.0, 122.7, 121.7, 120.7, 118.1, 118.04, 
118.00, 117.97, 115.7, 115.66, 115.62, 115.58, 111.6, 45.5. HRMS (m/z): calcd for C22H18F3N4 
(M+H) 395.1484; found 395.1481.  
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)  
-100102030405060708090100110120130140150160170180190200210




N4-Benzyl-N2-(3-iodophenyl)quinazoline-2,4-diamine (S91). Yield: 16.0 mg, 95%. 1H NMR 
(400 MHz, CDCl3) δ 8.38 (t, J = 1.9 Hz, 1H), 7.62 (tdd, J = 4.1, 5.9, 9.2 Hz, 4H), 7.50 – 7.31 (m, 
6H), 7.22 (ddd, J = 3.0, 5.2, 8.2 Hz, 2H), 7.02 (t, J = 8.0 Hz, 1H), 5.95 (s, 1H), 4.88 (d, J = 5.3 
Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 160.1, 156.5, 151.3, 141.6, 138.1, 133.1, 130.5, 130.2, 
128.9, 127.9, 127.8, 127.7, 126.5, 122.6, 120.7, 118.1, 111.5, 94.3, 45.5. HRMS (m/z): calcd for 





N4-Benzyl-N2-methyl-N2-phenylquinazoline-2,4-diamine (S92). Yield: 7.7 mg, 61%. 1H NMR 
(400 MHz, CDCl3) δ 7.36 (dd, J = 1.3, 4.6 Hz, 2H), 7.31 (t, J = 7.8 Hz, 1H), 7.26 – 7.09 (m, 7H), 
7.05 – 7.00 (m, 2H), 7.00 – 6.94 (m, 1H), 6.90 (ddd, J = 3.3, 4.9, 8.2 Hz, 1H), 5.58 (s, 1H), 4.38 
(d, J = 5.6 Hz, 2H), 3.45 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 159.2, 158.9, 152.2, 146.3, 
138.9, 132.5, 128.6, 128.4, 128.0, 127.3, 126.6, 126.5, 124.6, 121.3, 120.6, 110.9, 45.0, 38.2. 













N2-(3-Chlorophenyl)-N4-(4-methylbenzyl)quinazoline-2,4-diamine (S93). Yield: 13.0 mg, 
98%. 1H NMR (400 MHz, CDCl3) δ 8.08 (t, J = 2.0 Hz, 1H), 7.65 (d, J = 3.5 Hz, 2H), 7.57 (d, J 
= 8.2 Hz, 1H), 7.53 – 7.46 (m, 1H), 7.34 (d, J = 8.0 Hz, 2H), 7.25 – 7.20 (m, 4H), 7.06 (s, br. 
1H), 6.98 (ddd, J = 0.9, 2.0, 7.9 Hz, 1H), 5.86 (s, br. 1H), 4.83 (d, J = 5.3 Hz, 2H), 2.40 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 160.1, 156.5, 151.3, 141.7, 137.6, 135.1, 134.4, 133.0, 129.7, 
129.6, 127.9, 126.6, 122.6, 121.5, 120.7, 118.8, 116.8, 111.6, 45.2, 21.2. HRMS (m/z): calcd for 



























KSC-16-89   
N4-(4-Chlorobenzyl)-N2-(3-chlorophenyl)quinazoline-2,4-diamine (S94). Yield: 13.0 mg, 
100%. 1H NMR (400 MHz, CDCl3) δ 8.00 (t, J = 2.0 Hz, 1H), 7.63 – 7.61 (m, 2H), 7.55 (d, J = 
8.2, 1H), 7.45 – 7.38 (m, 1H), 7.33 (s, 4H), 7.22 – 7.19 (m, 1H), 7.17 (d, J = 8.1 Hz, 1H), 7.03 (s, 
br. 1H), 6.94 (dd, J = 1.1, 7.9 Hz, 1H), 5.90 (s, br. 1H), 4.82 (d, J = 5.6 Hz, 2H). 13C NMR (101 
MHz, CDCl3) δ 160.1, 156.4, 151.3, 141.5, 136.7, 134.4, 133.5, 133.2, 129.7, 129.1, 129.0, 
126.6, 122.7, 121.6, 120.6, 118.9, 116.9, 111.4, 44.6. HRMS (m/z): calcd for C21H17Cl2N4 (M+H) 








N2-(3-Chlorophenyl)-N4-(4-fluorobenzyl)quinazoline-2,4-diamine (S95 or 12). Yield: 13.0 
mg, 99%. 1H NMR (400 MHz, CDCl3) δ 8.00 (t, J = 2.0 Hz, 1H), 7.65 – 7.57 (m, 2H), 7.54 (d, J 
= 8.2 Hz, 1H), 7.44 – 7.38 (m, 1H), 7.35 (dd, J = 5.3, 8.7 Hz, 2H), 7.22 – 7.14 (m, 2H), 7.09 (s, 
br. 1H), 7.06 – 6.99 (m, 2H), 6.93 (ddd, J = 0.9, 2.0, 7.9 Hz, 1H), 5.89 (s, br. 1H), 4.80 (d, J = 
5.2 Hz, 2H).  13C NMR (101 MHz, CDCl3) δ 163.6, 161.1, 160.1, 156.4, 151.3, 141.6, 134.4, 
133.93, 133.90, 133.1, 130.0, 129.54, 129.46, 126.6, 122.7, 121.6, 120.7, 118.9, 116.9, 115.8, 






N4-(4-Bromobenzyl)-N2-(3-chlorophenyl)quinazoline-2,4-diamine (S96). Yield: 12.5 mg, 
99%. 1H NMR (400 MHz, CDCl3) δ 8.04 (t, J = 2.0 Hz, 1H), 7.72 – 7.63 (m, 2H), 7.60 (d, J = 
8.2 Hz, 1H), 7.57 – 7.48 (m, 2H), 7.48 – 7.40 (m, 1H), 7.31 (d, J = 8.5 Hz, 2H), 7.27 – 7.20 (m, 
2H), 7.05 (s, br. 1H), 7.02 – 6.90 (m, 1H), 5.94 (s, br. 1H), 4.85 (d, J = 5.6 Hz, 2H). 13C NMR 
(101 MHz, CDCl3) δ 160.1, 156.4, 151.4, 141.5, 137.3, 134.4, 133.2, 131.9, 129.7, 129.4, 126.7, 
122.7, 121.6, 121.5, 120.6, 118.9, 116.9, 111.4, 44.6. HRMS (m/z): calcd for C21H17BrClN4 
(M+H) 439.0325 and 441.0305; found 441.0296.  
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)  
-100102030405060708090100110120130140150160170180190200210











N2-(3-Chlorophenyl)-N4-(4-methoxybenzyl)quinazoline-2,4-diamine (S97). Yield: 11.3 mg, 
87%. 1H NMR (400 MHz, CDCl3) δ 8.09 (t, J = 2.1 Hz, 1H), 7.65 (d, J = 3.5 Hz, 2H), 7.56 (d, J 
= 8.2 Hz, 1H), 7.53 – 7.47 (m, 1H), 7.38 (d, J = 8.8 Hz, 2H), 7.23 (dt, J = 6.0, 8.2 Hz, 2H), 7.03 
(s, br. 1H), 6.99 (dd, J = 1.1, 7.9 Hz, 1H), 6.97 – 6.92 (m, 2H), 5.82 (s, br. 1H), 4.81 (d, J = 5.2 
Hz, 2H), 3.85 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 160.0, 159.3, 156.4, 151.2, 141.6, 134.4, 
133.0, 130.1, 129.7, 129.3, 126.5, 122.6, 121.6, 120.7, 118.9, 116.9, 114.3, 111.5, 55.4, 45.0. 
HRMS (m/z): calcd for C22H20ClN4O (M+H) 391.1326; found 391.1326.  
-100102030405060708090100110120130140150160170180190200210




N2-(3-Chlorophenyl)-N4-(2-methylbenzyl)quinazoline-2,4-diamine (S98). Yield: 12.8 mg, 
97%. 1H NMR (400 MHz, CDCl3) δ 8.07 (t, J = 2.0 Hz, 1H), 7.72 – 7.61 (m, 2H), 7.57 (d, J = 
8.1 Hz, 1H), 7.52 – 7.42 (m, 1H), 7.38 (d, J = 7.3 Hz, 1H), 7.32 – 7.30 (m, 2H), 7.28 – 7.13 (m, 
4H), 7.04 – 6.90 (m, 1H), 5.74 (s, br. 1H), 4.85 (d, J = 5.0 Hz, 2H), 2.44 (s, 3H). 13C NMR (101 
MHz, CDCl3) δ 160.1, 156.5, 151.3, 141.7, 136.8, 135.7, 134.4, 133.0, 130.7, 129.7, 128.6, 
128.1, 126.6, 126.4, 122.6, 121.5, 120.7, 118.9, 116.8, 111.5, 43.7, 19.2. HRMS (m/z): calcd for 
C22H20ClN4 (M+H) 375.1376; found 375.1376.  
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)  
-100102030405060708090100110120130140150160170180190200210




N4-(2-Chlorobenzyl)-N2-(3-chlorophenyl)quinazoline-2,4-diamine (S99). Yield: 13.0 mg, 
100%. 1H NMR (400 MHz, CDCl3) δ 8.02 (t, J = 2.1 Hz, 1H), 7.71 – 7.57 (m, 3H), 7.53 – 7.40 
(m, 3H), 7.29 – 7.18 (m, 4H), 7.14 – 6.93 (m, 2H), 6.12 (s, br. 1H), 4.98 (d, J = 5.8 Hz, 2H). 13C 
NMR (101 MHz, CDCl3) δ 160.1, 156.4, 151.4, 141.6, 135.5, 134.4, 133.8, 133.1, 129.9, 129.72, 
129.69, 129.0, 127.1, 126.6, 122.7, 121.6, 120.7, 118.9, 116.9, 111.6, 43.2. HRMS (m/z): calcd 
for C21H17Cl2N4 (M+H) 395.0830; found 395.0826.  
0.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)  
-100102030405060708090100110120130140150160170180190200210




N2-(3-Chlorophenyl)-N4-(2-fluorobenzyl)quinazoline-2,4-diamine (S100). Yield: 12.4 mg, 
94%. 1H NMR (400 MHz, CDCl3) δ 8.05 (t, J = 2.0 Hz, 1H), 7.71 – 7.57 (m, 3H), 7.53 – 7.40 (m, 
2H), 7.38 – 7.30 (m, 1H), 7.28 – 7.20 (m, 2H), 7.20 – 7.07 (m, 3H), 7.04 – 6.96 (m, 1H), 6.02 (s, 
br. 1H), 4.95 (d, J = 5.6 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 162.5, 160.1, 160.0, 156.4, 
151.3, 141.6, 134.4, 133.1, 130.2, 130.1, 129.7, 129.5, 129.4, 126.6, 125.2, 125.1, 124.41, 124.38, 
122.6, 121.6, 120.7, 119.0, 116.9, 115.7, 115.5, 111.6, 39.4, 39.3. HRMS (m/z): calcd for 






N4-(2-Bromobenzyl)-N2-(3-chlorophenyl)quinazoline-2,4-diamine (S101). Yield: 12.3 mg, 
98%. 1H NMR (400 MHz, CDCl3) δ 8.01 (t, J = 2.0 Hz, 1H), 7.67 – 7.62 (m, 4H), 7.49 – 7.45 (m, 
2H), 7.34 – 7.30 (m, 1H), 7.28 – 7.13 (m, 4H), 7.04 – 6.95 (m, 1H), 6.19 (s, br. 1H), 4.96 (d, J = 
5.7 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 160.0, 156.3, 151.2, 141.5, 137.1, 134.4, 133.1, 
133.0, 130.1, 129.7, 129.3, 127.8, 126.5, 123.8, 122.7, 121.7, 120.7, 119.0, 117.0, 111.5, 45.5. 
HRMS (m/z): calcd for C21H17BrClN4 (M+H) 439.0325 and 441.0305; found 441.0298.  
 
-100102030405060708090100110120130140150160170180190200210




N2-(3-Chlorophenyl)-N4-(2-methoxybenzyl)quinazoline-2,4-diamine (S102). Yield: 13.0 mg, 
100%. 1H NMR (400 MHz, CDCl3) δ 8.12 (t, J = 2.1 Hz, 1H), 7.68 – 7.59 (m, 2H), 7.56 (d, J = 
8.2 Hz, 1H), 7.48 (ddd, J = 0.9, 2.1, 8.2 Hz, 1H), 7.41 (dd, J = 1.7, 7.6 Hz, 1H), 7.38 – 7.30 (m, 
1H), 7.27 – 7.18 (m, 2H), 7.16 (s, br. 1H), 7.04 – 6.91 (m, 3H), 6.25 (s, br. 1H), 4.89 (d, J = 5.6 
Hz, 2H), 3.96 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 160.1, 157.8, 156.6, 151.3, 141.8, 134.4, 
132.8, 129.9, 129.6, 129.1, 126.5, 126.1, 122.4, 121.4, 120.8, 120.7, 118.9, 116.9, 111.8, 110.5, 







N2-(3-Chlorophenyl)-N4-(3-methylbenzyl)quinazoline-2,4-diamine (S103). Yield: 13.0 mg, 
98%. 1H NMR (400 MHz, CDCl3) δ 8.07 (t, J = 2.1 Hz, 1H), 7.65 (d, J = 3.5 Hz, 2H), 7.58 (d, J 
= 8.2 Hz, 1H), 7.49 (ddd, J = 0.9, 2.1 Hz, 8.2, 1H), 7.34 – 7.29 (m, 1H), 7.28 – 7.08 (m, 6H), 
6.98 (ddd, J = 0.9, 2.0, 7.9 Hz, 1H), 5.90 (s, br. 1H), 4.84 (d, J = 5.2 Hz, 2H), 2.40 (s, 3H). 13C 
NMR (101 MHz, CDCl3) δ 160.1, 156.5, 151.3, 141.6, 138.7, 138.0, 134.4, 133.0, 129.7, 128.8, 
128.7, 128.5, 126.6, 125.0, 122.6, 121.5, 120.7, 118.8, 116.8, 111.6, 45.4, 21.4. HRMS (m/z): 
calcd for C22H20ClN4 (M+H) 375.1376; found 375.1379.  
 
-100102030405060708090100110120130140150160170180190200210




N4-(3-Chlorobenzyl)-N2-(3-chlorophenyl)quinazoline-2,4-diamine (S104). Yield: 13.0 mg 
100%. 1H NMR (400 MHz, CDCl3) δ 8.02 (t, J = 2.0 Hz, 1H), 7.73 – 7.57 (m, 3H), 7.49 – 7.39 
(m, 2H), 7.33 – 7.32 (m, 3H), 7.29 – 7.18 (m, 2H), 7.12 (s, br. 1H), 7.05 – 6.93 (m, 1H), 5.98 (s, 
br. 1H), 4.88 (d, J = 5.5 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 160.1, 156.3, 151.2, 141.4, 
140.3, 134.7, 134.4, 133.2, 130.1, 129.7, 127.8, 127.7, 126.5, 125.8, 122.7, 121.7, 120.7, 119.0, 
117.0, 111.4, 44.7. HRMS (m/z): calcd for C21H17Cl2N4 (M+H) 395.0830; found 395.0826.  
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)  
-100102030405060708090100110120130140150160170180190200210




N2-(3-Chlorophenyl)-N4-(3-fluorobenzyl)quinazoline-2,4-diamine (S105). Yield: 13.0 mg, 
99%. 1H NMR (400 MHz, CDCl3) δ 8.02 (t, J = 2.0 Hz, 1H), 7.71 – 7.64 (m, 2H), 7.62 (d, J = 
8.2 Hz, 1H), 7.46 (d, J = 8.2 Hz, 1H), 7.41 – 7.33 (m, 1H), 7.28 – 7.23 (m, 1H), 7.21 (d, J = 8.0 
Hz, 2H), 7.15 – 7.12 (m, 2H), 7.04 (t, J = 8.2 Hz, 1H), 6.99 (dd, J = 1.1, 7.9 Hz, 1H), 6.00 (s, br. 
1H), 4.90 (d, J = 5.4 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 164.3, 161.9, 160.1, 156.4, 151.3, 
141.5, 140.9, 140.8, 134.4, 133.2, 130.4, 130.3, 123.0, 126.6, 123.2, 123.1, 122.7, 121.6, 120.6, 
118.9, 116.9, 114.66, 114.65, 114.5, 114.4, 111.4, 44.73, 44.71. HRMS (m/z): calcd for 
C21H17ClFN4 (M+H) 379.1126; found 379.1125.  
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0





N4-(3-Bromobenzyl)-N2-(3-chlorophenyl)quinazoline-2,4-diamine (S106). Yield: 12.3 mg, 
98%. 1H NMR (400 MHz, CDCl3) δ 8.01 (s, 1H), 7.68 – 7.62 (m, 3H), 7.58 (s, 1H), 7.47 (t, J = 
9.1 Hz, 2H), 7.36 (d, J = 7.7 Hz, 1H), 7.28 – 7.20 (m, 3H), 7.00 (d, J = 9.0 Hz, 1H), 6.04 (s, br. 
1H), 4.87 (d, J = 5.4 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 160.1, 156.3, 151.2, 141.4, 140.6, 
134.4, 133.2, 130.8, 130.7, 130.4, 129.7, 126.5, 126.2, 122.9, 122.7, 121.7, 120.7, 118.9, 116.9, 














N2-(3-Chlorophenyl)-N4-(3-methoxybenzyl)quinazoline-2,4-diamine (S107). Yield: 13.0 mg, 
100%. 1H NMR (400 MHz, CDCl3) δ 8.06 (t, J = 2.1 Hz, 1H), 7.70 – 7.62 (m, 2H), 7.59 (d, J = 
8.2 Hz, 1H), 7.48 (ddd, J = 0.9, 2.1, 8.2 Hz, 1H), 7.37 – 7.30 (m, 1H), 7.24 – 7.20 (m, 2H), 7.15 
(s, br. 1H), 7.03 (d, J = 7.5 Hz, 1H), 7.00 – 6.93 (m, 2H), 6.89 (dd, J = 1.9, 8.2 Hz, 1H), 5.93 (s, 
br. 1H), 4.85 (d, J = 5.3 Hz, 2H), 3.82 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 160.1, 160.0, 
156.5, 151.3, 141.6, 139.8, 134.4, 133.0, 130.0, 129.7, 126.6, 122.6, 121.5, 120.7, 120.0, 118.8, 
116.8, 113.6, 113.0, 111.5, 55.3, 45.4. HRMS (m/z): calcd for C22H20ClN4O (M+H) 391.1326; 











N4-Benzyl-N2-(4-methoxybenzyl)quinazoline-2,4-diamine (S108 or 13). Yield: 22.0 mg, 80%. 
1H NMR (400 MHz, DMSO) δ 8.44 (s, 1H), 8.03 (d, J = 7.3 Hz, 1H), 7.55 – 7.43 (m, 1H), 7.43 – 
7.11 (m, 8H), 7.04 (t, J = 7.1 Hz, 2H), 6.82 (s, br. 2H), 4.74 (d, J = 4.7 Hz, 2H), 4.43 (s, br. 2H), 
3.70 (s, 3H). 13C NMR (101 MHz, DMSO) δ 159.9, 159.8, 159.3, 157.8, 139.9, 133.2, 132.2, 
129.2, 128.5, 128.2, 127.3, 126.6, 122.7, 119.9, 113.5, 113.4, 54.9, 43.4, 43.3. HRMS (m/z): 
calcd for C23H23N4O (M+H) 371.1872; found 371.1868. 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0





N4-Benzyl-N2-(4-methylbenzyl)quinazoline-2,4-diamine (S109 or 45). Yield: 24.0 mg, 91%. 
1H NMR (400 MHz, CDCl3) δ 7.61 – 7.44 (m, 3H), 7.43 – 7.22 (m, 7H), 7.14 (d, J = 7.8 Hz, 2H), 
7.12 – 7.03 (m, 1H), 5.92 (s, br. 1H), 5.32 (s, br. 1H), 4.80 (d, J = 5.4 Hz, 2H), 4.70 (d, J = 5.1 
Hz, 2H), 2.36 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 160.1, 159.5, 152.2, 138.7, 137.0, 136.6, 
132.7, 129.2, 128.7, 128.0, 127.6, 127.5, 125.6, 121.1, 120.8, 111.0, 45.4, 45.1, 21.1. HRMS 
(m/z): calcd for C23H23N4 (M+H) 355.1923; found 355.1924.  
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0




KSC-16-33   
N4-Benzyl-N2-(4-chlorobenzyl)quinazoline-2,4-diamine (S110). Yield: 27.0 mg, 97%. 1H 
NMR (400 MHz, CDCl3) δ 7.61 – 7.55 (m, 1H), 7.51 (t, J = 8.1, 2H), 7.41 – 7.30 (m, 7H), 7.29 – 
7.277 (m, 2H), 7.14 – 7.10 (m, 1H), 5.83 (s, br. 1H), 5.33 (s, br. 1H), 4.79 (d, J = 5.5 Hz, 2H), 
4.71 (d, J = 6.0 Hz, 2H). HRMS (m/z): calcd for C22H20ClN4 (M+H) 375.1376; found 375.1369.  
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0






N4-Benzyl-N2-(4-fluorobenzyl)quinazoline-2,4-diamine (S111). Yield: 26.5 mg, 99%. 1H 
NMR (400 MHz, CDCl3) δ 7.58 (ddd, J = 1.4, 6.9, 8.2 Hz, 1H), 7.51 (t, J = 8.3 Hz, 2H), 7.43 – 
7.30 (m, 7H), 7.11 (ddd, J = 1.3, 6.9, 8.2 Hz, 1H), 7.00 (t, J = 8.7 Hz, 2H), 5.86 (s, br. 1H), 5.33 
(s, br. 1H), 4.80 (d, J = 5.5 Hz, 2H), 4.70 (d, J = 5.9 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 
163.1, 160.7, 160.1, 159.4, 152.1, 138.6, 135.9, 132.8, 129.2, 129.1, 128.8, 127.9, 127.6, 125.8, 
121.2, 120.9, 115.3, 115.1, 111.0, 45.1, 44.8. HRMS (m/z): calcd for C22H20FN4 (M+H) 
























N4-Benzyl-N2-(4-bromobenzyl)quinazoline-2,4-diamine (S112). Yield: 31.0 mg, 100%. 1H 
NMR (400 MHz, CDCl3) δ 7.62 – 7.54 (m, 1H), 7.50 (t, J = 7.6 Hz, 2H), 7.43 (d, J = 8.4 Hz, 
2H), 7.37 – 7.33 (m, 5H), 7.27 (d, J = 8.3 Hz, 2H), 7.12 (t, J = 8.1 Hz, 1H), 5.80 (s, br. 1H), 5.28 
(s, br.  1H), 4.79 (d, J = 5.5 Hz, 2H), 4.69 (d, J = 6.1 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 
160.1, 159.4, 152.1, 139.3, 138.5, 132.8, 131.5, 129.2, 128.8, 127.9, 127.6, 125.8, 121.3, 120.7, 
120.7, 111.1, 45.1, 44.9.  HRMS (m/z): calcd for C22H20BrN4 (M+H) 419.0871 and 421.0851; 
found 421.0846.  
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)  
-100102030405060708090100110120130140150160170180190200210




N4-Benzyl-N2-(2-methylbenzyl)quinazoline-2,4-diamine (S113). Yield: 25.0 mg, 95%. 1H 
NMR (400 MHz, CDCl3) δ 7.59 – 7.52 (m, 3H), 7.43 – 7.30 (m, 6H), 7.25 – 7.13 (m, 3H), 7.13 – 
7.04 (m, 1H), 5.93 (s, br. 1H), 5.19 (s, br. 1H), 4.80 (d, J = 5.4 Hz, 2H), 4.72 (d, J = 5.0 Hz, 2H), 
2.40 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 160.1, 159.4, 152.2, 138.7, 137.6, 136.4, 132.8, 
130.3, 128.8, 128.3, 128.0, 127.6, 127.2, 126.0, 125.7, 121.1, 120.8, 111.1, 45.1, 43.7, 19.1. 
HRMS (m/z): calcd for C23H23N4 (M+H) 355.1923; found 355.1920.  
 
-100102030405060708090100110120130140150160170180190200210




N4-Benzyl-N2-(2-chlorobenzyl)quinazoline-2,4-diamine (S114). Yield: 27.0 mg, 97%. 1H 
NMR (400 MHz, CDCl3) δ 7.62 – 7.54 (m, 1H), 7.50 (dd, J = 4.1, 7.7 Hz, 3H), 7.42 – 7.30 (m, 
6H), 7.24 – 7.14 (m, 2H), 7.10 (ddd, J = 1.2, 6.8, 8.1 Hz, 1H), 5.83 (s, br. 1H), 5.44 (s, br. 1H), 
4.84 (d, J = 6.3 Hz, 2H), 4.80 (d, J = 5.5 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 160.1, 159.4, 
152.2, 138.6, 137.6, 133.4, 132.8, 129.6, 129.3, 128.8, 128.2, 127.9, 127.5, 126.8, 125.8, 121.2, 
120.7, 111.0, 45.1, 43.2. HRMS (m/z): calcd for C22H20ClN4 (M+H) 375.1376; found 375.1376.  
0.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)  
-100102030405060708090100110120130140150160170180190200210




N4-Benzyl-N2-(2-fluorobenzyl)quinazoline-2,4-diamine (S115). Yield: 26.5 mg, 99%. 1H 
NMR (400 MHz, CDCl3) δ 7.51 – 7.43 (m, 1H), 7.40 (d, J = 7.9 Hz, 2H), 7.33 (s, 1H), 7.30 – 
7.20 (m, 5H), 7.17 – 7.07 (m, 1H), 7.05 – 6.88 (m, 3H), 5.73 (s, br. 1H), 5.27 (s, br. 1H), 4.72 – 
4.69  (m, 4H). 13C NMR (101 MHz, CDCl3) δ 162.3, 160.1, 159.8, 159.4, 152.2, 138.6, 132.8, 
129.9, 128.8, 128.6, 128.5, 127.9, 127.6, 127.2, 127.0, 125.7, 124.0, 124.0, 121.2, 120.7, 115.3, 




f1 (ppm)  
-100102030405060708090100110120130140150160170180190200210




N4-Benzyl-N2-(2-bromobenzyl)quinazoline-2,4-diamine (S116). Yield: 31.0 mg, 99%. 1H 
NMR (400 MHz, CDCl3) δ 7.58 (dd, J = 4.9, 11.7 Hz, 2H), 7.51 – 7.46 (m, 3H), 7.36 – 7.31 (m, 
5H), 7.23 (t, J = 7.3 Hz, 1H), 7.16 – 7.05 (m, 2H), 5.82 (s, br. 1H), 5.47 (s, br. 1H), 4.82 (d, J = 
6.4 Hz, 2H), 4.81 (d, J = 6.4 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 160.1, 159.4, 152.2, 139.2, 
138.6, 132.8, 132.6, 129.7, 128.8, 128.5, 127.9, 127.5, 127.4, 125.7, 123.5, 121.2, 120.7, 111.0, 





N4-Benzyl-N2-(2-methoxybenzyl)quinazoline-2,4-diamine (S117). Yield: 26.4 mg, 96%. 1H 
NMR (400 MHz, CDCl3) δ 7.61 – 7.43 (m, 3H), 7.43 – 7.30 (m, 6H), 7.28 – 7.20 (m, 1H), 7.11 – 
7.01 (m, 1H), 6.95 – 6.81 (m, 2H), 5.93 (s, br. 1H), 5.48 (s, br. 1H), 4.84 (d, J = 5.4 Hz, 2H), 
4.75 (d, J = 6.0 Hz, 2H), 3.86 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 160.1, 159.7, 157.6, 152.3, 
138.8, 132.6, 129.4, 128.7, 128.2, 128.1, 128.0, 127.5, 125.6, 120.8, 120.8, 120.4, 110.9, 110.1, 
55.3, 45.1, 41.1. HRMS (m/z): calcd for C23H23N4O (M+H) 371.1872; found 371.1869.  
0.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0





N4-Benzyl-N2-(3-methylbenzyl)quinazoline-2,4-diamine (S118). Yield: 26.0 mg, 99%. 1H 
NMR (400 MHz, CDCl3) δ 7.62 – 7.46 (m, 3H), 7.43 – 7.30 (m, 5H), 7.27 – 7.15 (m, 3H), 7.09 
(ddd, J = 1.4, 6.7, 8.1 Hz, 2H), 5.92 (s, br. 1H), 5.35 (s, br. 1H), 4.80 (d, J = 5.5 Hz, 2H), 4.72 (d, 
J = 5.1 Hz, 2H), 2.35 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 160.1, 159.5, 152.2, 140.0, 138.7, 
138.1, 132.8, 128.7, 128.4, 128.0, 127.7, 127.6, 125.7, 124.7, 121.1, 120.8, 111.1, 45.6, 45.1, 
21.4. HRMS (m/z): calcd for C23H23N4 (M+H) 355.1923; found 355.1922.  
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0





N4-Benzyl-N2-(3-chlorobenzyl)quinazoline-2,4-diamine (S119). Yield: 26.4 mg, 95%. 1H 
NMR (400 MHz, CDCl3) δ 7.52 – 7.44 (m, 1H), 7.41 (t, J = 8.0 Hz, 2H), 7.35 – 7.20 (m, 6H), 
7.18 – 7.09 (m, 3H), 7.06 – 6.98 (m, 1H), 5.75 (s, br. 1H), 5.28 (s, br. 1H), 4.68 (d, J = 5.5 Hz, 
2H), 4.62 (d, J = 6.1 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 160.1, 159.4, 152.1, 142.5, 138.6, 
134.3, 132.8, 129.7, 128.8, 127.9, 127.6, 127.1, 125.7, 125.6, 121.3, 120.8, 111.1, 45.1, 45.0. 
HRMS (m/z): calcd for C22H20ClN4 (M+H) 375.1376; found 375.1375.  
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0





N4-Benzyl-N2-(4-(trifluoromethyl)benzyl)quinazoline-2,4-diamine (S120 or 46). Yield: 30.0 
mg, 99%. 1H NMR (400 MHz, CDCl3) δ 7.59 – 7.48  (m, 7H), 7.33 – 7.31 (m, 5H), 7.11 (ddd, J 
= 1.3, 6.9, 8.2 Hz, 1H), 5.92 (s, br. 1H), 5.52 (s, br. 1H), 4.79 (d, J = 6.2 Hz, 2H), 4.77 (d, J = 5.5 
Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 160.1, 159.4, 152.1, 144.6, 138.5, 132.9, 129.2, 128.9, 
128.8, 127.8, 127.6, 125.7, 125.6, 125.4, 125.34, 125.30, 125.26, 122.9, 121.4, 120.8, 111.1, 






N4-Benzyl-N2-(3-methoxybenzyl)quinazoline-2,4-diamine (S121 or 47). Yield: 27.0 mg, 98%. 
1H NMR (400 MHz, CDCl3) δ 7.63 – 7.45 (m, 3H), 7.43 – 7.30 (m, 5H), 7.25 (t, J = 7.8 Hz, 1H), 
7.09 (ddd, J = 1.3, 6.8, 8.1 Hz, 1H), 6.99 (d, J = 8.1 Hz, 2H), 6.82 (dd, J = 1.9, 8.2 Hz, 1H), 5.89 
(s, br. 1H), 5.36 (s, br. 1H), 4.80 (d, J = 5.5 Hz, 2H), 4.73 (d, J = 5.1 Hz, 2H), 3.80 (s, 3H). 13C 
NMR (101 MHz, CDCl3) δ 160.1, 159.8, 159.5, 152.2, 141.8, 138.7, 132.8, 129.5, 128.7, 128.0, 
127.6, 125.7, 121.1, 120.8, 119.9, 113.1, 112.6, 111.1, 55.2, 45.6, 45.1. HRMS (m/z): calcd for 
C23H23N4O (M+H) 371.1872; found 371.1870.  
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0




KSC-16-36   
N4-Benzyl-N2-(3-fluorobenzyl)quinazoline-2,4-diamine (S122 or 48). Yield: 25.0 mg, 94%. 
1H NMR (400 MHz, CDCl3) δ 7.57 (ddd, J = 1.3, 6.8, 8.2 Hz, 1H), 7.51 (dd, J = 8.3, 11.7 Hz, 
2H), 7.42 – 7.30 (m, 5H), 7.29 – 7.23 (m, 1H), 7.20 – 7.04 (m, 3H), 6.94 (td, J = 1.9, 8.3 Hz, 1H), 
5.92 (s, br. 1H), 5.44 (s, br. 1H), 4.78 (d, J = 5.5 Hz, 2H), 4.74 (d, J = 5.9 Hz, 2H). 13C NMR 
(101 MHz, CDCl3) δ 164.2, 161.8, 160.1, 159.4, 152.1, 143.1, 143.0, 138.6, 132.8, 129.9, 129.8, 
128.8, 127.9, 127.6, 125.7, 123.0, 121.3, 120.8, 114.4, 114.2, 113.8, 113.6, 111.1, 45.1, 45.02, 






N4-Benzyl-N2-(3-bromobenzyl)quinazoline-2,4-diamine (S123 or 49). Yield: 29.4 mg, 95%. 
1H NMR (400 MHz, CDCl3) δ 7.62 – 7.54 (m, 2H), 7.51 (t, J = 7.4 Hz, 2H), 7.43 – 7.30 (m, 7H), 
7.18 (t, J = 7.8 Hz, 1H), 7.15 – 7.07 (m, 1H), 5.82 (s, br. 1H), 5.33 (s, br. 1H), 4.79 (d, J = 5.4 Hz, 
2H), 4.72 (d, J = 6.0 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 160.1, 159.4, 152.1, 142.8, 138.6, 
132.8, 130.5, 130.0, 128.8, 127.9, 127.6, 126.1, 125.7, 122.5, 121.3, 120.8, 111.1, 45.1, 44.9. 
HRMS (m/z): calcd for C22H20BrN4 (M+H) 419.0871 and 421.0851; found 419.0866.  
 
-100102030405060708090100110120130140150160170180190200210




N4-Benzyl-N2-(3,4-dichlorobenzyl)quinazoline-2,4-diamine (S124). Yield: 30.0 mg, 99%. 1H 
NMR (400 MHz, CDCl3) δ 7.57 (ddd, J = 1.4, 6.9, 8.3 Hz, 1H), 7.54 – 7.47 (m, 3H), 7.40 – 7.30 
(m, 6H), 7.18 (d, J = 8.1 Hz, 1H), 7.11 (ddd, J = 1.3, 6.9, 8.2 Hz, 1H), 5.97 (s, br. 1H), 5.59 (s, br. 
1H), 4.77 (d, J = 5.5 Hz, 2H), 4.66 (d, J = 6.0 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 160.2, 
159.3, 152.0, 140.9, 138.5, 132.9, 132.3, 130.6, 130.3, 129.3, 128.8, 127.8, 127.6, 126.8, 125.7, 
121.4, 120.8, 111.1, 45.1, 44.4. HRMS (m/z): calcd for C22H19Cl2N4 (M+H) 409.0987; found 
409.0980.  
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)  
-100102030405060708090100110120130140150160170180190200210




N4-Benzyl-N2-(4-chloro-3-(trifluoromethyl)benzyl)quinazoline-2,4-diamine (S125). Yield: 
32.0 mg, 97%. 1H NMR (400 MHz, CDCl3) δ 7.61 (s, 1H), 7.46 (ddd, J = 1.4, 6.9, 8.3 Hz, 1H), 
7.42 (d, J = 8.3 Hz, 1H), 7.39 – 7.32 (m, 2H), 7.32 – 7.19 (m, 6H), 7.01 (ddd, J = 1.2, 6.9, 8.2 Hz, 
1H), 5.83 (s, br. 1H), 5.50 (s, br. 1H), 4.65 (d, J = 5.5 Hz, 2H), 4.61 (d, J = 5.5 Hz, 2H). 13C 
NMR (101 MHz, CDCl3) δ 160.2, 159.3, 152.0, 139.8, 138.4, 132.9, 131.8, 131.4, 130.4, 128.8, 
128.3, 128.0, 127.7, 127.6, 126.62, 126.58, 125.7, 124.3, 121.6, 121.5, 120.8, 111.1, 45.1, 44.6. 
HRMS (m/z): calcd for C23H19ClF3N4 (M+H) 443.1250; found 443.1246.  
 
-100102030405060708090100110120130140150160170180190200210




N-Benzyl-2-(3,4-dihydroquinolin-1(2H)-yl)quinazolin-4-amine (S142). Yield: 12.4 mg, 91%. 
1H NMR (400 MHz, CDCl3) δ 7.76 (d, J = 7.2 Hz, 1H), 7.50 (dd, J = 1.0, 4.5 Hz, 2H), 7.46 (d, J 
= 8.2 Hz, 1H), 7.33 – 7.20 (m, 5H), 7.10 – 7.00 (m, 2H), 6.94 (dd, J = 4.1, 11.4 Hz, 1H), 6.87 (td, 
J = 1.2, 7.3 Hz, 1H), 5.73 (s, br. 1H), 4.69 (d, J = 5.5 Hz, 2H), 4.23 – 4.03 (m, 2H), 2.75 (t, J = 
6.6 Hz, 2H), 1.94 (dt, J = 6.6, 12.7 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 159.5, 158.1, 152.0, 
140.5, 138.8, 132.6, 130.3, 128.7, 128.4, 127.8, 127.5, 126.8, 125.1, 124.9, 122.3, 121.8, 120.6, 







N-Benzyl-2-(indolin-1-yl)quinazolin-4-amine (S143). Yield: 13.0 mg, 99%. 1H NMR (400 
MHz, CDCl3) δ 8.50 (d, J = 8.0 Hz, 1H), 7.76 – 7.53 (m, 3H), 7.52 – 7.32 (m, 5H), 7.23 – 7.11 
(m, 3H), 6.91 (t, J = 7.4 Hz, 1H), 5.90 (s, 1H), 4.94 (d, J = 5.4 Hz, 2H), 4.45 – 4.28 (m, 2H), 
3.19 (t, J = 8.7 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 159.7, 156.6, 151.9, 144.4, 138.6, 132.7, 
132.4, 128.8, 127.9, 127.6, 127.1, 126.7, 124.5, 121.8, 120.8, 120.7, 115.4, 110.9, 49.0, 45.7, 
27.3. HRMS (m/z): calcd for C23H21N4 (M+H) 353.1766; found 353.1761.  
 
-100102030405060708090100110120130140150160170180190200210









2-(2H-Benzo[b][1,4]oxazin-4(3H)-yl)-N-benzylquinazolin-4-amine (S144 or 15). Yield: 27.0 
mg, 99%. 1H NMR (400 MHz, CDCl3) δ 8.12 (d, J = 8.3 Hz, 1H), 7.68 – 7.61 (m, 2H), 7.58 (d, J 
= 8.2 Hz, 1H), 7.45 – 7.30 (m, 5H), 7.25 – 7.12 (m, 1H), 7.03 – 6.89 (m, 2H), 6.88 – 6.77 (m, 
1H), 5.94 (s, 1H), 4.84 (d, J = 5.5 Hz, 2H), 4.39 (dd, J = 3.1, 5.1 Hz, 2H), 4.34 (dd, J = 3.1, 5.0 
Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 159.8, 156.7, 151.7, 146.3, 138.5, 132.8, 128.8, 128.1, 
127.7, 127.6, 126.8, 124.7, 123.4, 122.3, 120.7, 119.4, 116.7, 111.3, 66.2, 45.3, 42.2. HRMS 
(m/z): calcd for C23H21N4O (M+H) 369.1715; found 369.1716. 
0.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)  
-100102030405060708090100110120130140150160170180190200210




N-Benzyl-2-(3,4-dihydroquinoxalin-1(2H)-yl)quinazolin-4-amine (S145). Yield: 13.5 mg, 
99%. 1H NMR (400 MHz, CDCl3) δ 7.82 (d, J = 7.8 Hz, 1H), 7.57 (dd, J = 6.2, 13.7 Hz, 3H), 
7.45 – 7.31 (m, 5H), 7.21 – 7.09 (m, 1H), 6.94 – 6.84 (m, 1H), 6.62 (dd, J = 4.4, 12.2 Hz, 2H), 
5.82 (s, br. 1H), 4.81 (d, J = 5.5 Hz, 2H), 4.40 – 4.25 (m, 2H), 3.55 – 3.45 (m, 2H). 13C NMR 
(101 MHz, CDCl3) δ 159.6, 157.2, 152.0, 138.7, 137.2, 132.6, 128.7, 127.8, 127.5, 126.7, 126.6, 
125.7, 123.8, 121.7, 120.6, 116.1, 114.6, 111.2, 45.2, 42.4, 41.5. HRMS (m/z): calcd for 
C23H22N5 (M+H) 368.1875; found 368.1874.  
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)  
-100102030405060708090100110120130140150160170180190200210




N-Benzyl-2-(3,4-dihydroquinoxalin-1(2H)-yl)-8-methoxyquinazolin-4-amine (S146). Yield: 
5.6 mg, 42%. 1H NMR (400 MHz, CDCl3) δ 7.72 (d, J = 7.8 Hz, 1H), 7.37 – 7.21 (m, 5H), 7.04 
(d, J = 7.8 Hz, 1H), 6.98 (t, J = 7.8 Hz, 1H), 6.92 (d, J = 7.7 Hz, 1H), 6.77 (t, J = 6.9 Hz, 1H), 
6.59 – 6.44 (m, 2H), 5.68 (s, 1H), 4.69 (d, J = 5.4 Hz, 2H), 4.33 – 4.24 (m, 2H), 3.92 (s, 3H), 
3.48 – 3.37 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 159.6, 156.8, 153.8, 138.7, 137.0, 128.7, 
127.9, 127.5, 126.7, 125.2, 123.5, 121.3, 118.8, 116.1, 114.5, 112.4, 111.7, 111.3, 56.2, 45.3, 
42.5, 41.5. HRMS (m/z): calcd for C24H24N5O (M+H) 398.1981; found 398.1974.  
 
-100102030405060708090100110120130140150160170180190200210




2-(2H-Benzo[b][1,4]oxazin-4(3H)-yl)-N-benzyl-8-methoxyquinazolin-4-amine (S147 or 38). 
Yield: 7.1 mg, 53%. 1H NMR (400 MHz, CDCl3) δ 8.21 – 8.08 (m, 1H), 7.46 – 7.31 (m, 5H), 
7.18  7.11 (m, 2H), 7.05 (dd, J = 1.6, 7.3 Hz, 1H), 6.99 – 6.88 (m, 2H), 6.80 (ddd, J = 2.3, 6.5, 
8.7 Hz, 1H), 5.86 (s, 1H), 4.83 (d, J = 5.5 Hz, 2H), 4.50 – 4.40 (m, 2H), 4.40 – 4.29 (m, 2H), 
4.03 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 159.7, 156.2, 153.9, 146.2, 143.6, 138.5, 128.8, 
128.1, 127.8, 127.6, 124.3, 123.2, 121.9, 119.4, 116.7, 112.3, 111.8, 111.4, 66.2, 56.1, 45.4, 42.2. 









(S156). Yield: 10.0 mg, 73%. 1H NMR (400 MHz, CDCl3) δ 7.77 (dd, J = 1.4, 8.1 Hz, 1H), 7.44 
– 7.30 (m, 5H), 7.14 (d, J = 6.9 Hz, 1H), 7.08 (t, J = 7.9 Hz, 1H), 7.05 – 7.01 (m, 1H), 6.96 (dd, 
J = 4.2, 11.2 Hz, 1H), 6.73 (dd, J = 1.3, 8.2 Hz, 1H), 6.58 (t, J = 7.6 Hz, 1H), 5.77 (s, 1H), 4.77 
(d, J = 5.4 Hz, 2H), 4.47 – 4.36 (m, 2H), 4.02 (s, 3H), 3.49 – 3.38 (m, 2H), 2.99 (s, 3H). 13C 
NMR (101 MHz, CDCl3) δ 159.5, 156.8, 153.8, 143.9, 139.4, 138.7, 128.7, 127.9, 127.5, 127.1, 
124.6, 123.7, 121.2, 115.3, 112.4, 111.7, 111.3, 111.1, 56.2, 51.0, 45.3, 41.8, 38.7. HRMS (m/z): 








(S157). Yield: 8.2 mg, 37%. 1H NMR (400 MHz, CDCl3) δ 7.34 – 7.21 (m, 5H), 7.15 – 6.87 (m, 
6H), 5.98 – 5.73 (m, 1H), 4.70 (d, J = 5.4 Hz, 2H), 4.19 (s, br. 2H), 3.96 (s, br. 2H), 3.92 (s, 3H), 
2.18 (s, 3H). HRMS (m/z): calcd for C26H26N5O2 (M+H) 440.2087; found 440.2096.  
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0







KSC-16-270 (probe)  
2-(2-Amino-1H-benzo[d]imidazol-1-yl)-N-benzyl-8-methoxyquinazolin-4-amine (S158 or 
ML240). Yield: 14.6 mg, 55%. 1H NMR (400 MHz, DMSO) δ 9.33 (t, J = 5.9 Hz, 1H), 8.31 – 
8.05 (m, 3H), 7.93 (d, J = 7.5 Hz, 1H), 7.50 – 7.39 (m, 3H), 7.39 – 7.30 (m, 3H), 7.25 (t, J = 7.3 
Hz, 1H), 7.15 (d, J = 7.1 Hz, 1H), 7.03 (td, J = 1.2, 7.6 Hz, 1H), 6.87 – 6.76 (m, 1H), 4.92 (d, J = 
5.8 Hz, 2H), 3.98 (s, 3H). 13C NMR (101 MHz, DMSO) δ 160.8, 154.7, 153.5, 153.4, 142.8, 
140.0, 138.5, 131.5, 128.5, 126.9, 126.6, 124.9, 122.5, 118.7, 114.8, 114.6, 114.1, 113.0, 112.7, 
56.1, 44.5. HRMS (m/z): calcd for C23H21N6O (M+H) 397.1777; found 397.1776.  
 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)  
-100102030405060708090100110120130140150160170180190200210




3-(4-(Benzylamino)-8-methoxyquinazolin-2-yl)benzo[d]oxazol-2(3H)-one (S159). Yield: 6.6 
mg, 25%. 1H NMR (400 MHz, DMSO) δ 9.22 (t, J = 6.0 Hz, 1H), 7.91 (d, J = 7.4 Hz, 1H), 7.83 
(d, J = 7.9 Hz, 1H), 7.50 (t, J = 8.1 Hz, 1H), 7.45 (d, J = 7.0 Hz, 2H), 7.40 (d, J = 7.9 Hz, 1H), 
7.38 – 7.31 (m, 3H), 7.27 (t, J = 7.3 Hz, 1H), 7.22 (t, J =  7.8 Hz, 1H), 7.15 (t, J = 7.8 Hz, 1H), 
4.86 (d, J = 5.9 Hz, 2H), 3.98 (s, 3H). 13C NMR (101 MHz, DMSO) δ 160.8, 154.3, 150.7, 150.1, 
141.6, 141.2, 139.1, 129.3, 128.4, 127.4, 126.9, 125.8, 123.8, 123.4, 114.1, 114.0, 113.8, 113.0, 































2-(1H-Benzo[d]imidazol-1-yl)-N-benzyl-8-methoxyquinazolin-4-amine (S160). Yield: 3.7 mg, 
19%. 1H NMR (500 MHz, DMSO) δ 9.27 (s, 1H), 9.08 (s, 1H), 8.72 (d, J = 7.5 Hz, 1H), 7.91 (d, 
J = 7.4 Hz, 1H), 7.74 (d, J = 7.4 Hz, 1H), 7.53 – 7.42 (m, 3H), 7.39 – 7.30 (m, 5H), 7.25 (d, J = 
7.4 Hz, 1H), 4.92 (d, J = 5.8 Hz, 2H), 4.01 (s, 3H). 13C NMR (126 MHz, DMSO) δ 160.6, 154.3, 
151.5, 144.5, 142.1, 141.2, 139.2, 131.8, 128.4, 127.2, 126.9, 125.1, 124.0, 123.1, 119.6, 115.9, 
114.14, 114.12, 113.0, 56.1, 44.3. HRMS (m/z): calcd for C23H20N5O (M+H) 382.1668; found 
382.1658.  
-100102030405060708090100110120130140150160170180190200210










(ML241). Yield: 9.0 mg, 66%. 1H NMR (400 MHz, CDCl3) δ 8.09 – 8.01 (m, 1H), 7.42 – 7.30 
(m, 5H), 6.92 – 6.86 (m, 2H), 6.80 – 6.73 (m, 1H), 4.79 (s, 1H), 4.69 (d, J = 5.6 Hz, 2H), 4.28 
(dd, J = 3.1, 5.0 Hz, 2H), 4.23 (dd, J = 3.1, 5.0 Hz, 2H), 2.67 (t, J = 5.7 Hz, 2H), 2.32 (t, J = 5.7 
Hz, 2H), 1.93 – 1.77 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 162.5, 160.7, 157.3, 145.9, 139.5, 
128.6, 128.5, 127.5, 127.3, 123.9, 122.6, 119.5, 116.6, 103.8, 65.9, 45.0, 42.2, 32.2, 22.6, 22.5, 
21.9. HRMS (m/z): calcd for C23H25N4O (M+H) 373.2028; found 373.2030.  
 
-100102030405060708090100110120130140150160170180190200210




2-(2H-Benzo[b][1,4]oxazin-4(3H)-yl)-N-benzylthieno[3,2-d]pyrimidin-4-amine (S162 or 17). 
Yield: 8.2 mg, 41%. 1H NMR (500 MHz, DMSO) δ 8.39 (t, J = 5.9 Hz, 1H), 8.01 (d, J = 5.3 Hz, 
1H), 7.86 (dd, J = 1.5, 8.3 Hz, 1H), 7.36 – 7.29 (m, 4H), 7.28 – 7.21 (m, 1H), 7.19 (d, J = 5.3 Hz, 
1H), 6.90 – 6.84 (m, 1H), 6.82 (dd, J = 1.7, 8.1 Hz, 1H), 6.68 (ddd, J = 1.7, 7.1, 8.6 Hz, 1H), 
4.66 (d, J = 5.9 Hz, 2H), 4.23 – 4.16 (m, 2H), 4.15 – 4.13 (m, 2H). 13C NMR (126 MHz, DMSO) 
δ 160.9, 157.7, 156.7, 145.6, 139.7, 133.0, 128.3, 128.2, 127.0, 126.6, 124.3, 123.7, 122.7, 119.1, 




f1 (ppm)  
S‐121 
 
KSC-25-28   
2-(2H-Benzo[b][1,4]oxazin-4(3H)-yl)-N-benzylpyrimidin-4-amine (S165 or 32). Yield: 20.0 
mg, 69%. 1H NMR (400 MHz, CDCl3) δ 8.08 – 7.96 (m, 2H), 7.45 – 7.30 (m, 5H), 7.01 – 6.89 
(m, 2H), 6.89 – 6.78 (m, 1H), 5.91 (d, J = 5.8 Hz, 1H), 5.13 (s, 1H), 4.57 (d, J = 5.0 Hz, 2H), 
4.35 – 4.27 (m, 2H), 4.27 – 4.17 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 162.6, 159.7, 156.2, 
146.3, 138.5, 128.7, 127.8, 127.5, 127.4, 124.4, 123.6, 119.6, 116.8, 66.0, 45.3, 42.1. HRMS 
(m/z): calcd for C19H19N4O (M+H) 319.1559; found 319.1555.  
 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)  
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3-(4-(Benzylamino)-8-methoxyquinazolin-2-yl)-1,1-dimethylurea (S169). Yield: 12.3 mg, 
70%.  1H NMR (400 MHz, CDCl3) δ 7.46 – 7.41 (m, 2H), 7.41 – 7.35 (m, 2H), 7.33 (dt, J = 2.2, 
5.6 Hz, 1H), 7.10 (dd, J = 2.2, 7.2 Hz, 1H), 7.01 – 6.93 (m, 2H), 5.78 (s, 1H), 4.84 (d, J = 5.4 Hz, 
2H), 3.99 (s, 3H), 3.29 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 159.5, 159.3, 153.2, 144.3, 139.0, 
128.7, 128.0, 127.4, 119.9, 112.5, 110.9, 110.2, 56.0, 45.2, 37.0. HRMS not detected because the 
product was not stable under LC conditions. 
0.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0





N-Benzyl-2-(3,4-dihydroisoquinolin-2(1H)-yl)quinazolin-4-amine (S170 or 20). Yield: 8.0 
mg, 59%. 1H NMR (400 MHz, CDCl3) δ 7.45 (d, J = 3.6 Hz, 2H), 7.41 (d, J = 8.2 Hz, 1H), 7.35 
(d, J = 7.3 Hz, 2H), 7.33 – 7.21 (m, 3H), 7.16 – 7.03 (m, 4H), 7.03 – 6.89 (m, 1H), 5.73 (s, br. 
1H), 4.95 (s, 2H), 4.78 (d, J = 5.4 Hz, 2H), 4.07 (t, J = 5.9 Hz, 2H), 2.84 (t, J = 5.9 Hz, 2H).  13C 
NMR (101 MHz, CDCl3) δ 159.6, 139.0, 135.5, 134.9, 132.6, 128.7, 128.6, 127.9, 127.5, 126.6, 
126.03, 125.95, 120.9, 120.7, 110.3, 46.4, 45.3, 41.5, 29.2. HRMS (m/z): calcd for C24H23N4 







2-((4-(Benzylamino)-8-methoxyquinazolin-2-yl)amino)phenol (S171). Yield: 21.3 mg, 86%. 
1H NMR (400 MHz, CDCl3) δ 7.47 – 7.31 (m, 5H), 7.16 – 7.10 (m, 3H), 7.10 – 7.06 (m, 1H), 
7.03 (td, J = 2.0, 6.8 Hz, 1H), 6.94 (d, J = 6.6 Hz, 2H), 6.87 – 6.78 (m, 1H), 6.08 (s, br. 1H), 4.83 
(d, J = 5.4 Hz, 2H), 3.99 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 160.3, 156.5, 153.2, 149.3, 
137.9, 128.9, 128.3, 128.0, 127.8, 125.3, 122.5, 121.8, 120.9, 119.6, 112.1, 111.9, 111.2, 56.1, 








N4-Benzyl-8-methoxy-N2-(1-phenylethyl)quinazoline-2,4-diamine (S172). Yield: 20.5 mg, 
80%. 1H NMR (400 MHz, CDCl3) δ 7.39 (d, J = 7.2 Hz, 2H), 7.36 – 7.24 (m, 7H), 7.23 – 7.16 
(m, 1H), 7.04 (dd, J = 2.2, 7.4 Hz, 1H), 6.96 (td, J = 4.3, 7.5 Hz, 2H), 5.77 (s, 1H), 5.52 (s, 1H), 
5.33 – 5.16 (m, 1H), 4.69 (dd, J = 9.4, 11.0 Hz, 2H), 3.99 (s, 3H), 1.53 (d, J = 6.9 Hz, 3H). 13C 
NMR (101 MHz, CDCl3) δ 160.0, 158.7, 153.1, 145.9, 144.3, 138.8, 128.7, 128.3, 128.0, 127.4, 
126.5, 126.0, 120.2, 112.5, 110.9, 110.7, 55.9, 51.1, 45.1, 23.5. HRMS (m/z): calcd for 







N4-Benzyl-N2-(cyclohexylmethyl)-8-methoxyquinazoline-2,4-diamine (S173). Yield: 19.5 mg, 
78%. 1H NMR (400 MHz, DMSO) δ 8.58 – 7.91 (m, 1H), 7.50 (d, J = 7.2 Hz, 1H), 7.28 (d, J = 
7.1 Hz, 2H), 7.22 (t, J = 7.5 Hz, 2H), 7.14 (t, J = 7.2 Hz, 1H), 6.91 (d, J = 7.5 Hz, 1H), 6.85 (t, J 
= 7.9 Hz, 1H), 6.79 – 6.12 (m, 1H), 4.63 (d, J = 5.7 Hz, 2H), 3.73 (s, 3H), 3.02 (s, 2H), 1.53 (s, 
br. 5H), 1.42 – 1.21 (m, 1H), 1.00 (s,  br., 3H), 0.72 (s, br., 2H). 13C NMR (101 MHz, DMSO) δ 
159.8, 159.1, 152.6, 144.1, 140.2, 128.1, 127.1, 126.5, 119.0, 114.3, 111.0, 55.2, 47.0, 43.5, 37.8, 




































N4-Benzyl-N2-(3-chlorophenyl)-8-methoxyquinazoline-2,4-diamine (S174 or 50). Yield: 9.6 
mg, 74%. 1H NMR (400 MHz, CDCl3) δ 8.03 (t, J = 2.1 Hz, 1H), 7.51 – 7.33 (m, 6H), 7.28 (d, J 
= 11.5 Hz, 1H), 7.23 – 7.12 (m, 3H), 7.07 (dd, J = 1.9, 7.1 Hz, 1H), 6.96 (ddd, J = 0.9, 2.0, 7.9 
Hz, 1H), 5.94 (s, br. 1H), 4.90 (d, J = 5.1 Hz, 2H), 4.05 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 
160.2, 156.3, 153.7, 141.7, 138.0, 134.4, 129.7, 128.9, 127.9, 127.8, 122.1, 121.4, 118.8, 116.7, 








N4-Benzyl-N2-(3-fluorophenyl)-8-methoxyquinazoline-2,4-diamine (S175 or 51). Yield: 12.2 
mg, 98%. 1H NMR (400 MHz, CDCl3) δ 7.73 (dt, J = 2.1, 11.8 Hz, 1H), 7.42 – 7.20 (m, 6H), 
7.15 – 7.00 (m, 4H), 6.96 (dd, J = 1.7, 7.3 Hz, 1H), 6.64 – 6.51 (m, 1H), 5.86 (s, 1H), 4.79 (d, J 
= 5.1 Hz, 2H), 3.95 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 164.5, 162.1, 160.2, 156.3, 153.7, 
143.3, 142.2, 142.1, 138.0, 129.7, 129.6, 128.9, 127.9, 127.8, 122.1, 114.0, 114.0, 112.4, 111.8, 
111.3, 108.1, 107.8, 106.1, 105.8, 56.1, 45.7. HRMS (m/z): calcd for C22H20FN4O (M+H) 





N4-Benzyl-8-methoxy-N2-(thiophen-2-ylmethyl)quinazoline-2,4-diamine (S176 or 52). Yield: 
17.9 mg, 71%. 1H NMR (400 MHz, DMSO) δ 8.33 (s, 1H), 7.53 (dd, J = 1.3, 8.0 Hz, 1H), 7.27 
(d, J = 7.2 Hz, 2H), 7.24 – 7.16 (m, 3H), 7.13 (dd, J = 6.0, 8.3 Hz, 1H), 6.98 – 6.83 (m, 3H), 6.83 
– 6.72 (m, 1H), 4.66 (d, J = 5.8 Hz, 2H), 4.57 (d, J = 5.7 Hz, 2H), 3.74 (s, 3H). 13C NMR (101 
MHz, DMSO) δ 159.9, 158.4, 152.8, 144.6, 143.8, 140.0, 128.2, 127.3, 126.6, 126.4, 124.7, 
124.2, 119.7, 114.2, 111.7, 111.3, 55.4, 45.1, 43.4. HRMS (m/z): calcd for C21H21N4OS (M+H) 


























N4-Benzyl-8-methoxy-N2-(thiazol-5-ylmethyl)quinazoline-2,4-diamine (S177). Yield: 18.7 
mg, 74%. 1H NMR (400 MHz, DMSO) δ 8.86 (s, 1H), 8.45 (s, 1H), 7.75 (s, 1H), 7.63 (d, J = 7.9 
Hz, 1H), 7.43 – 7.11 (m, 6H), 7.02 (d, J = 13.8 Hz, 2H), 4.83 – 4.55 (m, 4H), 3.84 (s, 3H). 13C 
NMR (101 MHz, DMSO) δ 160.0, 158.2, 153.3, 152.9, 143.6, 140.8, 139.9, 128.2, 127.2, 126.6, 
119.9, 114.2, 111.9, 111.4, 55.5, 43.4, 36.6. HRMS (m/z): calcd for C20H20N5OS (M+H) 






N4-Benzyl-N2-(3-fluoro-5-methylphenyl)-8-methoxyquinazoline-2,4-diamine (S178). Yield: 
11.1 mg, 86%. 1H NMR (400 MHz, CDCl3) δ 7.53 (d, J = 11.7 Hz, 1H), 7.41 – 7.22 (m, 5H), 
7.12 – 7.00 (m, 2H), 7.00 – 6.89 (m, 2H), 6.41 (d, J = 9.3 Hz, 1H), 5.84 (s, 1H), 4.80 (d, J = 5.1 
Hz, 2H), 3.95 (s, 3H), 2.20 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 164.4, 162.0, 160.2, 156.4, 
153.7, 141.8, 141.7, 140.1, 140.0, 138.0, 128.9, 127.9, 127.8, 122.0, 114.6, 112.4, 111.7, 111.3, 
109.0, 108.7, 103.3, 103.0, 56.1, 45.7, 21.58, 21.56. HRMS (m/z): calcd for C23H22FN4O (M+H) 







(S179 or 40). Yield: 2.9 mg, 22%.  1H NMR (400 MHz, CDCl3) δ 8.12 – 7.87 (m, 1H), 7.25 (s, 
br. 2H), 7.14 – 7.02 (m, 2H), 6.98 – 6.93 (m, 2H), 6.84 (s, br. 2H), 6.78 – 6.56 (m, 1H), 5.89 – 
5.66 (m, 1H), 4.69 (s, br. 2H), 4.32 (s, br. 2H), 4.24 (s, br. 2H), 3.92 (s, 3H). 13C NMR (126 
MHz, CDCl3) δ 163.2, 161.2, 159.7, 134.2, 129.5, 124.4, 123.3, 122.0, 119.4, 116.7, 115.6, 
115.5, 112.3, 111.7, 111.4, 66.2, 56.2, 44.6, 42.2, 29.7. HRMS (m/z): calcd for C24H22FN4O2 
(M+H) 417.1727; found 417.1726.  
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amine (S180 or 41). Yield: 15.9 mg, 80%. 1H NMR (400 MHz, CDCl3) δ 8.25 (dd, J = 1.4, 8.2 
Hz, 1H), 7.27 (dd, J = 1.3, 5.1 Hz, 1H), 7.19 – 7.09 (m, 2H), 7.08 – 7.02 (m, 2H), 6.99 (ddd, J = 
2.5, 4.1, 8.1 Hz, 1H), 6.95 (dd, J = 1.8, 4.0 Hz, 1H), 6.93 – 6.86 (m, 1H), 5.90 (s, 1H), 4.98 (d, J 
= 5.1 Hz, 2H), 4.47 (dd, J = 3.6, 5.3 Hz, 2H), 4.37 (dd, J = 3.6, 5.3 Hz, 2H), 4.02 (s, 3H). 13C 
NMR (101 MHz, CDCl3) δ 159.3, 156.1, 153.9, 146.2, 143.6, 141.2, 128.1, 126.9, 126.2, 125.4, 
124.4, 123.3, 122.0, 119.5, 116.7, 112.4, 111.7, 111.5, 66.2, 56.1, 42.3, 40.2. HRMS (m/z): calcd 






(S181 or 42). Yield: 13.6 mg, 69%. 1H NMR (400 MHz, CDCl3) δ 8.26 (dd, J = 1.4, 8.1 Hz, 1H), 
7.20 – 7.09 (m, 2H), 7.03 (dd, J = 1.9, 7.1 Hz, 1H), 7.01 – 6.86 (m, 3H), 5.69 (s, 1H), 4.46 (dd, J 
= 3.6, 5.2 Hz, 2H), 4.37 (dd, J = 3.6, 5.2 Hz, 2H), 4.02 (s, 3H), 3.54 – 3.42 (m, 2H), 187 – 1.71 
(m, 6H), 1.40 – 1.13 (m, 4H), 1.04 (q, J = 12.0 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 160.0, 
156.4, 153.9, 146.2, 143.4, 128.2, 124.4, 123.1, 121.7, 119.3, 116.7, 112.2, 111.9, 111.2, 66.2, 
56.1, 47.6, 42.2, 37.8, 31.1, 26.5, 25.9. HRMS (m/z): calcd for C24H29N4O2 (M+H) 405.2291; 






























(S182). Yield: 7.4 mg, 56%. 1H NMR (400 MHz, CDCl3) δ 8.53 (s, 1H), 8.10 (s, 1H), 7.59 (td, J 
= 1.7, 7.7 Hz, 1H), 7.32 (s, br. 1H), 7.22 (d, J = 7.8 Hz, 1H), 7.18 – 7.12 (m, 1H), 7.09 (t, J = 8.0 
Hz, 1H), 6.96 (d, J = 7.1 Hz, 1H), 6.93 – 6.77 (m, 3H), 4.79 (d, J = 4.6 Hz, 2H), 4.39 – 4.32 (m, 
2H), 4.28 – 4.22 (m, 2H), 3.92 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 159.7, 156.6, 149.0, 
146.3, 136.7, 124.2, 123.3, 122.4, 122.2, 119.4, 116.8, 112.2, 122.0, 111.5, 66.2, 56.1, 45.9, 42.3. 

































(S183 or 43). Yield: 11.0 mg, 51%. 1H NMR (400 MHz, CDCl3) δ 8.91 (s, br. 1H), 7.97 (s, br. 
1H), 7.14 – 7.04 (m, 3H), 7.01 (t, J = 7.9 Hz, 1H), 6.93 (d, J = 8.8 Hz, 1H), 6.91 – 6.85 (m, 2H), 
6.82 (t, J = 7.3 Hz, 1H), 6.73 (t, J = 7.2 Hz, 2H), 4.68 (s, br. 2H), 4.30 (s, 4H), 3.87 (s, 3H). 13C 
NMR (101 MHz, CDCl3) δ 159.9, 155.8, 146.3, 130.8, 129.9, 124.0, 122.8, 119.9, 119.7, 117.4, 
117.2, 112.6, 112.1, 111.7, 66.0, 56.1, 43.1, 42.0. HRMS (m/z): calcd for C24H23N4O3 (M+H) 





























(S184). Yield: 7.0 mg, 36%. 1H NMR (400 MHz, CDCl3) δ 8.01 (s, 1H), 7.13 – 7.11 (m, 3H), 
7.03 (t, J = 8.0 Hz, 1H), 6.94 (d, J = 8.6 Hz, 1H), 6.91 – 6.78 (m, 2H), 6.72 (d, J = 8.4 Hz, 3H), 
4.62 (d, J = 5.0 Hz, 2H), 4.31 (d, J = 4.5 Hz, 2H), 4.23 (d, J = 4.6 Hz, 2H), 3.90 (s, 3H). 13C 
NMR (101 MHz, CDCl3) δ 159.6, 155.3, 146.3, 130.2, 129.3, 124.2, 123.5, 122.1, 119.5, 116.8, 
115.6, 112.7, 111.8, 111.6, 66.2, 56.1, 44.9, 42.3. HRMS (m/z): calcd for C24H23N4O3 (M+H) 







amine (S185). Yield: 4.6 mg, 36%. 1H NMR (400 MHz, CDCl3) δ 8.16 (s, 1H), 7.31 (s, br. 1H), 
7.21 (d, J = 7.2 Hz, 2H), 7.14 (d, J = 7.5 Hz, 1H), 7.04 – 6.97 (m, 3H), 6.94 – 6.91 (m, 1H), 6.89 
– 6.85 (m, 2H), 6.84 – 6.74 (m, 1H), 4.82 (d, J = 5.1 Hz, 2H), 4.40 – 4.36 (m, 2H), 4.29 – 4.27 
(m, 2H), 3.92 (s, 3H), 2.71 (s, 6H). 13C NMR (126 MHz, CDCl3) δ 159.8, 132.2, 129.6, 128.4, 
124.4, 124.0, 121.8, 120.0, 119.3, 116.7, 112.4, 112.3, 111.2, 66.2, 56.1, 44.7, 43.4, 42.2. HRMS 








amine (S186). Yield: 5.7 mg, 44%. 1H NMR (400 MHz, CDCl3) δ 8.39 – 8.15 (m, 1H), 7.26 (s, 
1H), 7.14 (s, 2H), 7.05 (s, 1H), 6.94 (s, 2H), 6.90 – 6.82 (m, 1H), 6.76 (d, J = 7.1 Hz, 2H), 6.71 
(d, J = 8.0 Hz, 1H), 5.93 – 5.72 (m, 1H), 4.77 (s, br. 2H), 4.46 (s, br. 2H), 4.36 (s, br. 2H), 4.02 
(s, 3H), 2.95 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 159.7, 151.0, 139.2, 129.5, 124.4, 123.1, 
121.8, 119.5, 116.7, 116.0, 112.4, 112.2, 111.4, 111.8, 111.8, 66.2, 56.1, 46.2, 42.2, 40.6. HRMS 







yl)amino)methyl)phenyl)carbamate (S187). Yield: 5.4 mg, 23%. 1H NMR (400 MHz, CDCl3) 
δ 8.24 – 8.06 (m, 1H), 7.81 (d, J = 7.5 Hz, 2H), 7.64 (d, J = 7.5 Hz, 2H), 7.44 (t, J = 7.4 Hz, 2H), 
7.41 – 7.30 (m, 5H), 7.23 – 7.09 (m, 2H), 7.06 (s, 1H), 6.94 (s, 2H), 6.88 – 6.78 (m, 1H), 6.78 – 
6.61 (m, 1H), 5.99 – 5.71 (m, 1H), 4.77 (s, br. 2H), 4.58 (d, J = 6.5 Hz, 2H), 4.42 (s, br. 2H), 
4.34 – 4.28  (m, 3H), 4.02 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 159.7, 153.4, 143.7, 141.4, 
137.0, 128.6, 127.8, 127.6, 127.2, 124.9, 120.1, 119.0, 111.8, 66.9, 66.2, 56.2, 47.1, 44.9, 42.2, 







(S188). Yield: 10.1 mg, 76%. 1H NMR (400 MHz, CDCl3) δ 8.71 (s, 1H), 8.29 – 8.01 (m, 1H), 
7.82 (s, 1H), 7.16 (s, 2H), 7.06 (d, J = 8.6 Hz, 1H), 6.96 – 6.84 (m, 3H), 6.28 – 5.93 (m, 1H), 
5.03 (d, J = 5.5 Hz, 2H), 4.53 – 4.42 (m, 2H), 4.42 – 4.29 (m, 2H), 4.01 (s, 3H). 13C NMR (126 
MHz, CDCl3) δ 159.3, 156.0, 153.6, 146.4, 143.7, 142.1, 135.7, 127.8, 124.4, 123.6, 122.2, 
119.5, 116.9, 113.9, 112.4, 111.7, 66.3, 56.1, 42.4, 37.3. HRMS (m/z): calcd for C21H20N5O2S 





General procedure B: representative protocol for the synthesis of 8-O-alkylatedquinazoline 




Scheme S2. Synthesis of 8-O-alkylated quinazolines 
 
2-(2H-Benzo[b][1,4]oxazin-4(3H)-yl)-4-(benzylamino)quinazolin-8-ol (S148). To a solution 
of 2-(2H-benzo[b][1,4]oxazin-4(3H)-yl)-N-benzyl-8-methoxyquinazolin-4-amine (2.6 mg, 6.5 
mol) in 0.5 mL of DCM at 0 ºC, was added BBr3 (39 L, 39 mol, 1M in DCM). The mixture 
was stirred at room temperature for 16 h. The reaction was quenched with slow addition of water. 
After extraction with DCM, the organic layer was dried over MgSO4, evaporated under vacuum 
to give the product. Yield: 19.0 mg, 62%. 1H NMR (400 MHz, CDCl3) δ 7.88 (s, 1H), 7.30 (d, J 
= 4.6 Hz, 4H), 7.28 – 7.21 (m, 1H), 7.09 - 7.06 (m, 2H), 7.02 – 6.88 (m, 2H), 6.86 (d, J = 6.5 Hz, 
1H), 6.79 – 6.74 (m, 1H), 4.76 (d, J = 5.4 Hz, 2H), 4.23 (s, 4H). HRMS (m/z): calcd for 





(S155 or 39). To a suspension of 2-(2H-benzo[b][1,4]oxazin-4(3H)-yl)-4-
(benzylamino)quinazolin-8-ol (0.012 g, 0.031 mmol) and K2CO3 (0.013 g, 0.094 mmol) in 1 mL 
of DMF, was added 2-chloroacetonitrile (3.0 µl, 0.047 mmol). The mixture was stirred at 80 °C 
for 16 h. The reaction was monitored by LC-MS. The reaction was complete after 16 h. DMF 
was removed under vacuum. The product was purified by SGC (EtOAc/hexanes = 1:2, Rf = 0.6). 
Yield: 3.3 mg, 25%. 1H NMR (400 MHz, CDCl3) δ 7.99 (dd, J = 1.5, 8.3 Hz, 1H), 7.34 – 7.29 (m, 3H), 
7.29 – 7.22 (m, 4H), 7.07 – 7.01 (m, 1H), 6.93 – 6.81 (m, 2H), 6.79 – 6.71 (m, 1H), 5.84 (s, 1H), 5.11 (s, 
2H), 4.73 (d, J = 5.4 Hz, 2H), 4.31 – 4.25 (m, 2H), 4.22 (dd, J = 3.1, 5.0 Hz, 2H). 13C NMR (126 MHz, 
CDCl3) δ 159.8, 156.1, 150.2, 146.5, 144.6, 138.1, 128.9, 127.7, 124.9, 123.9, 121.6, 121.1, 119.4, 116.9, 
116.8, 115.8, 112.6, 66.1, 56.5, 45.5, 42.2. HRMS (m/z): calcd for C25H22N5O2 (M+H) 424.1773; found 
424.1783.  
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0






or 33). Yield: 3.7 mg, 33%. 1H NMR (400 MHz, CDCl3) δ 8.05 (d, J = 7.3 Hz, 1H), 7.39 (dd, J = 
5.9, 7.5 Hz, 6H), 7.20 (d, J = 6.7 Hz, 1H), 7.12 (t, J = 7.9 Hz, 1H), 6.99 (d, J = 6.9 Hz, 1H), 6.97 
– 6.91 (m, 1H), 6.84 (t, J = 7.6 Hz, 1H), 4.84 (d, J = 5.5 Hz, 2H), 4.34 (s, 4H), 4.29 – 4.18 (m, 
2H), 3.92 – 3.81 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 159.8, 146.5, 138.2, 128.8, 127.8, 
127.6, 127.4, 124.4, 124.1, 122.4, 119.5, 118.6, 117.0, 114.9, 112.2, 73.6, 66.1, 60.8, 45.4, 42.5. 





KSC-25-29   
2-(2H-Benzo[b][1,4]oxazin-4(3H)-yl)-N-benzyl-8-(2-methoxyethoxy)quinazolin-4-amine 
(S151 or 34). Yield: 3.6 mg, 27%. 1H NMR (400 MHz, CDCl3) δ 8.28 (d, J = 7.7 Hz, 1H), 7.40 - 
7.39 (m, 4H), 7.37 – 7.32 (m, 1H), 7.21 - 719 (m, 1H), 7.13 – 7.09 (m, 2H), 6.99 – 6.88 (m, 2H), 
6.83 – 6.79 (m, 1H), 5.86 (s, br. 1H), 4.83 (d, J = 5.4 Hz, 2H), 4.45 – 4.38 (m, 2H), 4.38 – 4.27 
(m, 4H), 3.97 – 3.88 (m, 2H), 3.56 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 159.7, 156.0, 153.2, 
146.2, 143.9, 138.4, 128.8, 128.1, 127.7, 127.6, 124.5, 123.2, 121.9, 119.4, 116.6, 114.0, 113.0, 
111.9, 71.1, 68.8, 66.1, 59.5, 45.4, 42.1, 29.7. HRMS (m/z): calcd for C26H27N4O3 (M+H) 

































amine (S152 or 35). Yield: 4.1 mg, 64%. 1H NMR (400 MHz, CDCl3) δ 7.98 – 7.79 (m, 1H), 
7.31 – 7.22 (m, 6H), 7.05 (s, 2H), 6.85 (s, 2H), 6.70 (s, 1H), 4.75 (d, J = 5.5, 2H), 4.58 (s, 2H), 
4.21 (s, 4H), 3.48 (s, 2H), 3.21 (d, J = 7.3, 4H), 1.32 (t, J = 7.3, 6H). HRMS (m/z): calcd for 




























KSC-25-30   
2-(2H-Benzo[b][1,4]oxazin-4(3H)-yl)-N-benzyl-8-butoxyquinazolin-4-amine (S154 or 37). 
Yield: 4.9 mg, 61%. 1H NMR (400 MHz, CDCl3) δ 8.37 (d, J = 8.2 Hz, 1H), 7.47 – 7.31 (m, 5H), 
7.20 – 7.07 (m, 2H), 7.04 (dd, J = 1.5, 7.5 Hz, 1H), 7.00 – 6.89 (m, 2H), 6.89 – 6.77 (m, 1H), 
5.85 (s, 1H), 4.84 (d, J = 5.4 Hz, 2H), 4.48 – 4.38 (m, 2H), 4.35 – 4.32 (m, 2H), 4.15 (t, J = 6.5 
Hz, 2H), 2.04 – 1.89 (m, 2H), 1.72 – 1.62 (m, 2H), 1.08 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, 
CDCl3) δ 159.7, 155.9, 153.6, 146.2, 143.7, 138.5, 128.8, 128.3, 127.7, 127.6, 124.4, 123.1, 
121.9, 119.5, 116.6, 112.7, 112.1, 111.8, 68.6, 66.1, 45.4, 42.1, 31.4, 19.4, 14.0. HRMS (m/z): 

































General Procecedure C: representative protocol for the one-pot synthesis of quinazoline 
analogues, synthesis and characterization for S129, S126-S128, S130-S141. 
 
Scheme S3. Quinazoline synthesis  via the one-pot protocol. 
 
KSC-16-102  
N2,N4-Dibenzyl-6,7-dimethoxyquinazoline-2,4-diamine (S129). To a suspension of 2,4-
dichloro-6,7-dimethoxyquinazoline (50.0 mg, 0.19 mmol) in CH3CN (2 mL) was added 
benzylamine (0.11 mL, 0.96 mmol, 5 equiv.). The mixture was heated to 180 °C for 1 h under 
microwave irradiation. The solvent was removed under vacuum, the residue was suspended in 
EtOAc, washed with saturated NaHCO3, and the layers were separated. The organic layer was 
dried over MgSO4 and concentrated under vacuum. The residue was purified by SGC (EtOAc, 
Rf = 0.5) to give the product (66.0 mg, 85%). 1H NMR (400 MHz, CDCl3) δ 7.46 – 7.16 (m, 
10H), 6.94 (s, 1H), 6.89 (s, 1H), 6.31 (s, 1H), 5.41 (s, 1H), 4.80 (d, J = 5.5 Hz, 2H), 4.70 (d, J = 
5.7 Hz, 2H), 3.87 (s, 3H), 3.80 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 159.3, 159.0, 154.6, 148.5, 
145.6, 140.1, 139.1, 128.6, 128.5, 128.1, 127.5, 127.4, 126.9, 105.3, 103.8, 101.1, 56.1, 56.0, 

















N2,N4-Dibenzyl-5-chloroquinazoline-2,4-diamine (S126). Yield: 66.0 mg, 82%. 1H NMR (400 
MHz, CDCl3) δ 7.93 (s, br. 1H), 7.51 – 7.21 (m, 12H), 7.06 (dd, J = 2.5, 6.3 Hz, 1H), 5.60 (s, br. 
1H), 4.78 (d, J = 5.2 Hz, 2H), 4.72 (d, J = 6.0 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 159.6, 
159.1, 155.2, 140.0, 138.5, 131.9, 129.1, 128.7, 128.5, 127.7, 127.6, 127.4, 127.0, 125.3, 123.3, 
109.1, 45.6, 45.4. HRMS (m/z): calcd for C22H20ClN4 (M+H) 375.1376; found 375.1377.  
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)  
-100102030405060708090100110120130140150160170180190200210




N2,N4-Dibenzyl-5-fluoroquinazoline-2,4-diamine (S127). Yield: 12.8 mg, 39%. 1H NMR (400 
MHz, CDCl3) δ 7.30 (dd, J = 8.2, 14.8 Hz, 1H), 7.22 – 7.17 (m , 8H), 7.12 – 7.08 (m, 2H), 6.82 – 
6.63 (m, 1H), 6.58 (dd, J = 7.9, 12.7 Hz, 1H), 4.69 – 4.61 (m, 2H), 4.57 (d, J = 5.9 Hz, 2H). 13C 
NMR (101 MHz, CDCl3) δ 161.2, 159.8, 159.0, 158.7, 154.5, 139.8, 138.5, 132.5, 132.4, 128.7, 
128.5, 127.7, 127.6, 127.5, 127.1, 121.3, 106.3, 106.1, 45.5, 45.0. HRMS (m/z): calcd for 
C22H20FN4 (M+H) 359.1672; found  359.1676.  
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)  
-100102030405060708090100110120130140150160170180190200210




N2,N4-Dibenzyl-6-chloroquinazoline-2,4-diamine (S128). Yield: 56.0 mg, 70%. 1H NMR (400 
MHz, CDCl3) δ 7.55 – 7.21 (m, 13H), 5.78 (s, br. 1H), 5.40 (s, br. 1H), 4.77 (d, J = 5.4 Hz, 2H), 
4.73 (d, J = 5.9 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 159.5, 159.2, 150.7, 139.8, 138.3, 133.2, 
128.8, 128.5, 128.0, 127.7, 127.6, 127.2, 127.1, 126.0, 120.3, 45.6, 45.2. HRMS (m/z): calcd for 






N2,N4-Dibenzyl-8-methoxyquinazoline-2,4-diamine (S130 or 14). Yield: 14.9 mg, 18%. 1H 
NMR (400 MHz, CDCl3) δ 7.44 – 7.18 (m, 11H), 7.11 (dd, J = 1.6, 7.9 Hz, 1H), 7.07 – 6.93 (m, 
2H), 5.86 (s, br. 1H), 5.49 (s, br. 1H), ), 4.78 (d, J = 5.7 Hz, 2H), 4.75 (d, J = 5.7 Hz, 2H), 3.99 (s, 
3H). 13C NMR (101 MHz, CDCl3) δ 160.1, 159.3, 153.2, 144.2, 140.2, 138.7, 128.7, 128.4, 
128.0, 127.5, 126.8, 120.4, 112.5, 111.2, 110.9, 55.9, 45.7, 45.2. HRMS (m/z): calcd for 








N2,N4-Dibenzyl-7-methylquinazoline-2,4-diamine (S131). Yield: 83.0 mg, 99%. 1H NMR (400 
MHz, CDCl3) δ 7.47 – 7.19 (m, 12H), 6.93 (dd, J = 1.4, 8.3 Hz, 1H), 5.75 (s, br. 1H), 5.28 (s, br. 
1H), 4.79 (d, J = 5.5 Hz, 2H), 4.75 (d, J = 4.5 Hz, 2H), 2.44 (s, 3H). 13C NMR (101 MHz, CDCl3) 
δ 156.0, 159.7, 152.4, 143.3, 140.2, 138.8, 128.7, 128.5, 128.0, 127.6, 127.5, 126.9, 125.2, 123.0, 
120.6, 108.9, 45.6, 45.0, 21.8. HRMS (m/z): calcd for C23H23N4 (M+H) 355.1923; found 
355.1924.  
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)  
-100102030405060708090100110120130140150160170180190200210




N2,N4-Dibenzyl-7-(trifluoromethyl)quinazoline-2,4-diamine (S132). Yield: 75.0 mg, 98%. 1H 
NMR (400 MHz, CDCl3) δ 7.78 (s, 1H), 7.60 (d, J = 8.5 Hz, 1H), 7.39 – 7.33 (m, 9H), 7.32 – 
7.21 (m, 2H), 5.91 (s, br. 1H), 5.51 (s, br. 1H), 4.80 (d, J = 5.4 Hz, 2H), 4.75 (d, J = 5.9 Hz, 2H). 
13C NMR (101 MHz, CDCl3) δ 160.0, 159.7, 152.0, 139.6, 138.2, 134.8, 134.5, 134.2, 133.9, 
128.8, 128.6, 128.0, 127.8, 127.6, 127.1, 125.2, 123.2, 122.5, 121.9, 119.7, 116.64, 116.61, 112.8, 
45.5, 45.2.HRMS (m/z): calcd for C23H20F3N4 (M+H) 409.1640; found 409.1642.  
 
-100102030405060708090100110120130140150160170180190200210




N2,N4-Dibenzyl-8-bromoquinazoline-2,4-diamine (S133). Yield: 75.0 mg, 99%. 1H NMR (400 
MHz, CDCl3) δ 7.86 (dd, J = 1.1, 7.6 Hz, 1H), 7.68 – 7.19 (m, 11H), 6.90 (t, J = 7.8 Hz, 1H), 
5.89 (s, br. 1H), 5.74 – 5.16 (m, 1H), 4.77 (d, J = 5.4 Hz, 4H). 13C NMR (101 MHz, CDCl3) δ 
160.3, 159.8, 149.9, 139.9, 138.4, 136.1, 128.8, 128.4, 128.0, 127.6, 127.0, 120.9, 120.4, 45.7, 


















N2,N4-Dibenzyl-8-fluoroquinazoline-2,4-diamine (S134). Yield: 70.0 mg, 85%. 1H NMR (400 
MHz, CDCl3) δ 7.47 – 7.12 (m, 12H), 6.95 (td, J = 4.9, 8.0 Hz, 1H), 6.15 (s, br. 1H), 5.68 (s, br. 
1H), 4.77 (d, J = 5.5 Hz, 2H), 4.74 (d, J = 5.7 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 159.7, 
159.6, 157.4, 154.9, 142.7, 142.6, 140.0, 138.5, 128.7, 128.5, 128.0, 127.6, 127.0, 119.8, 119.7, 
117.0, 116.9, 116.6, 116.6, 112.8, 45.6, 45.1. . HRMS (m/z): calcd for C22H20FN4 (M+H) 
359.1672; found 359.1675.  
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)  
-100102030405060708090100110120130140150160170180190200210




N2,N4-Dibenzyl-7-fluoroquinazoline-2,4-diamine (S135). Yield: 37.0 mg, 45%. 1H NMR (400 
MHz, CDCl3) δ 7.49 (dd, J = 5.9, 9.0 Hz, 1H), 7.46 – 7.31 (m, 9H), 7.30 – 7.23 (m, 1H), 7.12 (d, 
J = 10.3 Hz, 1H), 6.82 (td, J = 2.5, 8.6 Hz, 1H), 5.81 (s, br. 1H), 5.41 (s, br. 1H), 4.78 (d, J = 5.4 
Hz, 2H), 4.73 (d, J = 5.9 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 167.0, 164.5, 160.1, 159.8, 
154.5, 154.3, 139.8, 138.5, 128.8, 128.5, 128.0, 127.6, 127.1, 123.1, 123.0, 110.4, 110.1, 45.5, 
























N2,N4-Dibenzyl-7-chloroquinazoline-2,4-diamine (S136). Yield: 74.0 mg, 92%. 1H NMR (400 
MHz, CDCl3) δ 7.54 (s, br. 1H), 7.50 – 7.37 (m, 10H), 7.32 (d, J = 7.0 Hz, 1H), 7.08 (dd, J = 2.1, 
8.7 Hz, 1H), 5.82 (s, br. 1H), 5.42 (s, br. 1H), 4.83 (d, J = 5.4 Hz, 2H), 4.79 (d, J = 5.9 Hz, 2H). 
13C NMR (101 MHz, CDCl3) δ 160.1, 159.8, 153.3, 139.8, 138.7, 138.4, 128.8, 128.5, 128.0, 
127.7, 127.6, 127.1, 124.8, 122.2, 121.6, 109.5, 45.5, 45.1. HRMS (m/z): calcd for C22H20ClN4 
(M+H) 375.1376; found 375.1377.  
 
-100102030405060708090100110120130140150160170180190200210




N2,N4-Dibenzyl-7-methoxyquinazoline-2,4-diamine (S137). Yield: 47.0 mg, 58%. 1H NMR 
(400 MHz, CDCl3) δ 7.33 – 7.08 (m, 11H), 6.75 (s, 1H), 6.57 (dd, J = 2.5, 8.9 Hz, 1H), 5.72 (s, 
br. 1H), 5.32 (s, br. 1H), 4.64 (d, J = 5.5 Hz, 2H), 4.61 (d, J = 5.8 Hz, 2H), 3.72 (s, 3H). 13C 
NMR (101 MHz, CDCl3) δ 163.4, 160.1, 159.9, 154.5, 140.1, 138.9, 128.7, 128.5, 128.0, 127.6, 
127.5, 127.0, 122.3, 112.7, 105.2, 104.9, 55.4, 45.6, 45.0. HRMS (m/z): calcd for C23H23N4O 
(M+H) 371.1872; found 371.1872.  
 
-100102030405060708090100110120130140150160170180190200210




N2,N4-Dibenzyl-6-methoxyquinazoline-2,4-diamine (S138). Yield: 22.5 mg, 46%. 1H NMR 
(400 MHz, CDCl3) δ 7.36 (d, J = 9.1 Hz, 1H), 7.32 – 7.08 (m, 11H), 6.77 (d, J = 2.7 Hz, 1H), 
5.80 (s, 1H), 5.17 (s, 1H), 4.69 (d, J = 5.4 Hz, 2H), 4.61 (d, J = 5.4 Hz, 2H), 3.70 (s, 3H). 13C 
NMR (101 MHz, CDCl3) δ 159.6, 158.6, 154.3, 147.3, 140.2, 138.9, 128.7, 128.4, 128.0, 127.6, 
127.5, 127.0, 126.9, 123.4, 110.8, 101.4, 55.7, 45.7, 45.1. HRMS (m/z): calcd for C23H23N4O 





N2,N4-Dibenzyl-6-fluoroquinazoline-2,4-diamine (S139). Yield: 12 mg, 24%. 1H NMR (400 
MHz, CDCl3) δ 7.49 (dd, J = 5.2, 9.1 Hz, 1H), 7.43 – 7.30 (m, 10H), 7.27 (d, J = 7.2 Hz, 1H), 
7.16 (dd, J = 2.7, 9.0 Hz, 1H), 5.70 (s, br. 1H), 5.40 (s, br. 1H), 4.78 (d, J = 5.4 Hz, 2H), 4.73 (d, 
J = 5.7 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 159.7, 159.6, 159.2, 158.4, 156.0, 148.9, 140.0, 
138.4, 128.8, 128.5, 128.0, 127.7, 127.6, 127.0, 122.0, 121.8, 110.7, 110.6, 105.5, 105.3, 103.0, 






N2,N4-Dibenzyl-7-bromoquinazoline-2,4-diamine (S140). Yield: 12.7 mg, 17%. 1H NMR (400 
MHz, CDCl3) δ 7.67 (s, br. 1H), 7.47 – 7.32 (m, 10H), 7.31 – 7.25 (m, 1H), 7.17 (dd, J = 1.9, 8.6, 
1H), 5.78 (s, br. 1H), 5.37 (s, br. 1H), 4.77 (d, J = 5.4 Hz, 2H), 4.73 (d, J = 5.9 Hz, 2H). 13C 
NMR (101 MHz, CDCl3) δ 159.9, 159.9, 153.5, 139.8, 138.3, 128.8, 128.5, 128.0, 127.7, 127.6, 
127.2, 127.1, 124.2, 122.1, 45.5, 45.2. HRMS (m/z): calcd for C22H20BrN4 (M+H) 419.0871 and 
421.0851; found 421.0845.  
 
-100102030405060708090100110120130140150160170180190200210




2,4-Bis(benzylamino)quinazoline-7-carbonitrile (S141). Yield: 12.3 mg, 15%. 1H NMR (400 
MHz, CDCl3) δ 7.79 (s, br. 1H), 7.55 (d, J = 8.3 Hz, 1H), 7.47 – 7.30 (m, 10H), 7.24 (dd, J = 1.6, 
8.3 Hz, 1H), 5.83 (s, 1H), 5.55 – 5.32 (m, 1H), 4.78 (d, J = 5.4 Hz, 2H), 4.74 (d, J = 6.0 Hz, 2H). 
13C NMR (101 MHz, CDCl3) δ 159.9, 159.5, 139.4, 137.9, 128.9, 128.6, 128.0, 127.9, 127.6, 























General procedure D: representative protocol for the synthesis of quinazoline analogues of less 
nucleophilic amines, synthesis and characterization for S166, S161, S163 (31), S164, S167 (19), 
S168. 
 
Scheme S4: Synthesis of quinazoline analogues of less nucleophilic amines 
 
KSC-25-22  
N2-(Benzo[d]thiazol-2-yl)-N4-benzyl-8-methoxyquinazoline-2,4-diamine (S166). To a 
suspension of N-benzyl-2-chloro-8-methoxyquinazolin-4-amine (15.0 mg, 50 mol) in CH3CN 
(1 mL) was added 2-aminobenzo[d]thiazole (15.0 mg, 0.1 mmol, 2 equiv.). The mixture was 
heated to 180 °C for 10 h under microwave irradiation. The solvent was removed under vacuum, 
the residue was suspended in EtOAc, washed with saturated NaHCO3, and the layers were 
separated. The organic layer was dried over MgSO4 and concentrated under vacuum. The residue 
was purified by reverse phase preparative HPLC to give the product (7.2 mg, 35%).1H NMR 
(400 MHz, DMSO) δ 11.43 (s, br. 1H), 8.91 (s, 1H), 7.91 – 7.75 (m, 2H), 7.62 (d, J = 7.8 Hz, 
1H), 7.48 (d, J = 7.2 Hz, 2H), 7.40 – 7.30 (m, 3H), 7.30 – 7.11 (m, 4H), 4.94 (d, J = 5.6 Hz, 2H), 
3.96 (s, 3H). 13C NMR (126 MHz, DMSO) δ 160.3, 160.2, 153.5, 153.3, 149.7, 141.8, 139.3, 
132.4, 128.3, 127.5, 126.8, 125.5, 122.9, 121.9, 120.8, 119.2, 117.7, 114.1, 112.5, 55.8, 44.1. 












KSC-25-31   
2-(2-Amino-1H-benzo[d]imidazol-1-yl)-N-benzyl-5,6,7,8-tetrahydroquinazolin-4-amine 
(S161, 18). Yield: 1.8 mg, 12%.  1H NMR (400 MHz, DMSO) δ 7.92 (d, J = 7.4 Hz, 1H), 7.84 (s, 
1H), 7.65 (s, 2H), 7.40 – 7.29 (m, 4H), 7.23 (s, 1H), 7.11 (d, J = 7.1 Hz, 1H), 6.99 (t, J = 7.0 Hz, 
1H), 6.79 – 6.72 (m, 1H), 4.71 (d, J = 6.0 Hz, 2H), 2.70 (s, br.  2H), 2.49 (s, br. 2H), 1.83 (s, br. 
4H). 13C NMR (126 MHz, DMSO) δ 161.0, 160.8, 154.3, 154.1, 142.8, 139.3, 131.6, 128.3, 
126.7, 126.4, 122.2, 118.6, 114.6, 114.3, 108.6, 44.1, 31.3, 21.9, 21.7, 21.6. HRMS (m/z): calcd 





KSC-25-24   
2-(2H-Benzo[b][1,4]oxazin-4(3H)-yl)-N-benzyl-5,6-dimethylpyrimidin-4-amine (S163 or 31). 
(Reaction time = 6 h) Yield: 6.5 mg, 46%. 1H NMR (400 MHz, CDCl3) δ 8.13 – 7.99 (m, 1H), 
7.42 – 7.30 (m, 5H), 6.94 – 6.87 (m, 2H), 6.81 – 6.74 (m, 1H), 4.82 (s, 1H), 4.69 (d, J = 5.6 Hz, 
2H), 4.31 – 4.26 (m, 2H), 4.29 – 4.23 (m, 2H), 2.35 (s, 3H), 2.01 (s, 3H). 13C NMR (101 MHz, 
CDCl3) δ 161.7, 160.9, 157.2, 145.9, 139.5, 128.6, 128.4, 127.5, 127.2, 124.0, 122.7, 119.5, 
116.6, 101.8, 65.9, 45.3, 42.2, 22.2, 10.9. HRMS (m/z): calcd for C21H23N4O (M+H) 347.1872; 





KSC-25-32   
1-(4-(Benzylamino)pyrimidin-2-yl)-1H-benzo[d]imidazol-2-amine (S164). Yield: 11.7 mg, 
48%. 1H NMR (400 MHz, DMSO) δ 8.51 (s, 1H), 8.16 (s, 1H), 8.05 (s, 1H), 7.75 (s, 2H), 7.41 – 
7.35 (m, 4H), 7.28 (s, 1H), 7.15 (d, J = 7.6 Hz, 1H), 7.05 – 7.02 (m, 1H), 6.83 (t, J = 7.8 Hz, 1H), 
6.51 (d, J = 5.8 Hz, 2H), 4.66 (s, 2H). 13C NMR (101 MHz, DMSO) δ 162.6, 156.9, 154.4, 153.8, 
143.0, 138.7, 131.5, 128.5, 127.0, 122.6, 118.8, 114.7, 114.6, 102.5, 101.3, 43.9. HRMS (m/z): 









(S167 or 19). Yield: 3.9 mg, 19%. 1H NMR (500 MHz, DMSO) δ 9.36 (s, 1H), 8.28 (s, 1H), 8.24 
(d, J = 8.0 Hz, 1H), 7.93 (d, J = 7.9 Hz, 1H), 7.51 (s, 1H), 7.50 – 7.39 (m, 2H), 7.35 (td, J = 2.7, 
9.5 Hz, 3H), 7.25 (t, J = 7.3 Hz, 1H), 7.16 (d, J = 5.4 Hz, 2H), 6.93 (s, 1H), 4.88 (d, J = 5.7 Hz, 
2H), 3.99 (s, 3H), 3.42 (s, 3H). HRMS (m/z): calcd for C24H23N6O (M+H) 411.1933; found 
411.1937.  
0.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0








1-(4-(Benzylamino)-8-methoxyquinazolin-2-yl)urea (S168). (Reaction time = 3 h) Yield: 4.7 
mg, 47%. 1H NMR (500 MHz, DMSO) δ 8.32 (d, J = 7.1 Hz, 1H), 7.58 (dd, J = 1.3, 8.2 Hz, 1H), 
7.36 (d, J = 7.0 Hz, 2H), 7.31 (dd, J = 4.9, 10.3 Hz, 2H), 7.23 (t, J = 7.2 Hz, 1H), 7.01 (d, J = 6.7 
Hz, 1H), 6.96 (t, J = 7.9 Hz, 1H), 6.13 (s, 2H), 4.73 (d, J = 5.9 Hz, 2H), 3.81 (s, 3H). 13C NMR 
(126 MHz, DMSO) δ 160.2, 159.8, 152.6, 143.6, 139.9, 128.2, 127.9, 127.3, 126.6, 119.5, 114.0, 






General procedure E: representative protocol for the synthesis of quinazoline analogues via a 
Suzuki coupling route, synthesis and characterization for S153 (36) and S149. 
 
 




(S153 or 36). A mixture of 2-(2H-benzo[b][1,4]oxazin-4(3H)-yl)-N-benzyl-8-bromoquinazolin-
4-amine (12.0 mg, 26.8 mol), palladium acetate (0.6 mg, 2.7 mol), [1,1'-biphenyl]-2-
yldicyclohexylphosphine (1.9 mg, 5.4 mol), 4-methoxyphenylboronic acid (6.1 mg, 40.2 mol), 
potassium fluoride (4.7 mg, 80.5 mol) in 0.5 mL of THF was heated at 50 ºC for 16 h. The 
mixture was diluted with EtOAc and washed with water. The orgainc phase was concentrated 
and purified by SGC (DCM/MeOH = 1:9, Rf = 0.5). Yield: 12 mg, 94%. 1H NMR (400 MHz, 
CDCl3) δ 8.17 – 8.09 (m, 1H), 7.75 – 7.69 (m, 2H), 7.68 (dd, J = 1.4, 7.3 Hz, 1H), 7.56 (dd, J = 
1.3, 8.2 Hz, 1H), 7.40 (dd, J = 1.9, 3.5 Hz, 4H), 7.39 – 7.32 (m, 1H), 7.28 – 7.21 (m, 1H), 7.07 – 
7.00 (m, 2H), 6.92 (dtd, J = 1.6, 8.1, 9.9 Hz, 2H), 6.77 – 6.70 (m, 1H), 5.94 (s, 1H), 4.85 (t, J = 
5.3 Hz, 2H), 4.33 – 4.25 (m, 4H), 3.92 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 160.1, 158.8, 
156.1, 149.5, 146.2, 138.6, 137.6, 133.1, 131.9, 131.6, 128.8, 128.2, 127.7, 127.6, 125.1, 123.2, 
121.9,  119.5, 119.4, 116.5, 113.2, 111.6,  66.1, 55.4, 45.5,  42.1. HRMS (m/z): calcd for 










































2-(2H-Benzo[b][1,4]oxazin-4(3H)-yl)-N-benzyl-8-phenylquinazolin-4-amine (S149). Yield: 
3.9 mg, 33%. 1H NMR (400 MHz, CDCl3) δ 8.03 (d, J = 7.0 Hz, 1H), 7.69 – 7.55 (m, 3H), 7.50 
(d, J = 7.0 Hz, 1H), 7.38 (t, J = 7.4 Hz, 2H), 7.34 – 7.22 (m, 5H), 7.18 – 7.11 (m, 1H), 6.79 (dt, J 
= 6.6, 8.1 Hz, 2H), 6.62 (dd, J = 4.3, 10.9 Hz, 1H), 5.86 (s, 1H), 4.76 (d, J = 5.4 Hz, 2H), 4.18 (s, 
4H). 13C NMR (126 MHz, CDCl3) δ 160.0, 156.1, 149.5, 146.2, 139.5, 138.5, 138.1, 133.5, 
130.5, 128.8, 128.2, 127.7, 127.7, 127.6, 126.9, 125.0, 123.2, 121.8, 120.0, 119.4, 116.4, 111.6, 
66.0, 45.5, 42.0. HRMS (m/z): calcd for C29H25N4O (M+H) 445.2028; found 445.2025.  
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